
•Title: A Randomized, Investigator and Subjects Blinded, Sponsor Unblinded, Placebo-Controlled, 
Phase 1 Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Escalating Multiple Doses 
of TAK-831 in Healthy Subjects
Study ID: [REMOVED]
Protocol Approve Date: 19 March 2018
Certain information  within this protocol has been  redacted (ie,  specific content is masked irreversibly from 
view with a black/blue bar) to protect either personally identifiable information (PPD) or company 
confidential information (CCI). 
This may include, but is not limited to, redaction of the following: 
Named persons or organizations associated with the study.
Proprietary information, such as scales or coding systems, which are considered confidential  
information under prior agreements with license holder.
Other information as needed to protect confidentiality of Takeda or partners, personal  information, or 
to otherwise protect the integrity of the clinical study.
TITLE PAGE
TAKEDA PHARMACEUTICALS
PROTOCOL
A Randomized, Investigator and Subject Blinded, Sponsor Unblinded, Placebo -Controlled, 
Phase 1 Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Escalating Multiple 
Doses of TAK -831 in Healthy Subjects
Study Identifier: TAK-831-1005
Compound: TAK-831
Date: 19March 2018
Version/Amendment 
Number:Amendment No. 02
Amendment History:
Date Amendment Number Region
08 June 2017 Initial version Global
15 August 2017 01 Global
19March 2018 02 Global
CONFIDENTIAL PROPERTY OF TAKEDA
This document is a confidential communication of Takeda. Acceptance of this document constitutes the agreement by 
the recipient that no information contained herein will be published or disclosed without written authorization from 
Takeda except to the extent necessary to obtain informed consent from those persons to whom the drug may be 
administered. Furthermore, the information is only meant for review and compliance by the recipient, his or her s taff, 
and applicable institutional review committee and regulatory agencies to enable conduct of the study.
TAK -831
TAK -831-1005 Page 2of 84
Protocol Incorporating Amendment No. 02 19 March 2018
CONFIDENTIALTABLE OF CONTENTS
1.0 STUDY SUMMARY ...................................................................................................... 6
1.1 Protocol  Amendment No. 02 Summary  of Changes ................................................... 9
2.0 STUDY SCHEMATIC .................................................................................................. 10
3.0 SCHEDULE OF STUDY PR OCEDURES .................................................................... 11
4.0 INTRODUCTION ......................................................................................................... 15
4.1 Backgrou nd............................................................................................................. 15
4.2 Rationale for the Proposed Study ............................................................................. 15
4.3 Benefit/Risk Profile .................................................................................................16
5.0 TRIAL OBJECTIVES AND ENDPOINTS ................................................................... 17
5.1 Trial Object ives....................................................................................................... 17
5.1.1 Trial Primary  Objective ...................................................................................... 17
5.1.2 Trial Secondary  Objective .................................................................................. 17
5.1.3 Trial Expl oratory  Object ives.............................................................................. 17
5.2 Endpoints ................................................................................................................. 17
5.2.1 Primary Endpo ints............................................................................................. 17
5.2.2 Secondary  Endpo ints.......................................................................................... 17
5.2.3 Exploratory  Endpo ints....................................................................................... 18
6.0 TRIAL DESIGN AND DES CRIPTION ........................................................................ 19
6.1 Trial Design ............................................................................................................. 19
6.2 Dose Esc alation....................................................................................................... 20
6.3 Rationale for Tri al Design, Dose, and Endpoints ...................................................... 22
6.3.1 Rationale of Tri al Desi gn................................................................................... 22
6.3.2 Rationale for Dose ............................................................................................. 22
6.3.3 Rationale for Endpoints ...................................................................................... 23
6.3.4 Critical Procedures Based on Trial Object ives: Timing of Procedures ................ 24
6.4 Trial Design/Dosin g/Procedures Modificat ions Permitted Within Protocol 
Param eters ............................................................................................................... 24
6.5 Trial Beginning and End/Complet ion....................................................................... 25
6.5.1 Definit ion of Beginning o f the Tri al................................................................... 25
6.5.2 Definit ion of End of the Trial ............................................................................. 25
6.5.3 Definit ion of Trial Com pletion........................................................................... 26
6.5.4 Definit ion of Trial Discont inuat ion.................................................................... 26
6.5.5 Criteria for Premature Terminat ion or Suspension of the Trial ............................ 26
6.5.6 Criteria for Premature Terminat ion or Suspension of a Site ................................ 27
TAK -831
TAK -831-1005 Page 3of 84
Protocol Incorporating Amendment No. 02 19 March 2018
CONFIDENTIAL6.5.7 Procedures for Premature Termination or Suspension of the Study  or a Si te....... 27
7.0 SELECTION AND DISCONTINUATION/WITHDRAWAL OF SUBJECTS .............. 28
7.1 Inclusio n Cri teria..................................................................................................... 28
7.2 Exclusion Criteria.................................................................................................... 28
7.2.1 Addit ional Exclusio n Cri teria for Cohort(s) Wi th CSF Co llection...................... 30
7.3 Excluded Medicat ions, Supplements, Dietary  Products ............................................ 31
7.4 Diet, Fl uid, Act ivity.................................................................................................32
7.4.1 Diet and Fluid .................................................................................................... 32
7.4.2 Activity.............................................................................................................. 32
7.5 Criteria for Di scontinuati onor Wi thdrawal  of a Subject ........................................... 33
7.6 Procedures for Discont inuat ion or Withdrawal o f a Subject ...................................... 34
7.7 Subject Replacement ................................................................................................ 34
8.0 CLINICAL STUDY MATER IAL MANAGEMENT ..................................................... 35
8.1 Clinical Study  Drug .................................................................................................35
8.1.1Clinical Study  Drug Labeling ............................................................................. 35
8.1.2 Clinical Study  Drug Inventory  and Storage ........................................................ 35
8.1.3 Clinical Study  Drug Blinding ............................................................................. 35
8.1.4 Randomization Code Creation and Storage ........................................................ 35
8.1.5 Clinical Trial Blind Maintenance/Unblinding Procedure .................................... 35
8.1.6 Accountabilit y and Destruction of Sponsor -Supplied Drugs ............................... 36
9.0 STUDY PROCEDURES ............................................................................................... 37
9.1 Administrative Procedures ....................................................................................... 37
9.1.1 Inform ed Consent Procedure .............................................................................. 37
9.1.2 Inclusio n and Exclusio n..................................................................................... 38
9.1.3 Medical History /Dem ography ............................................................................ 38
9.1.4 Medicat ion History /Concomitant Medications ................................................... 38
9.2 Clinical Procedures and Assessments ....................................................................... 38
9.2.1 Full Physical Examinat ion.................................................................................. 38
9.2.2 Height and Wei ght............................................................................................. 39
9.2.3BMI ................................................................................................................... 39
9.2.4 Vital Signs ......................................................................................................... 39
9.2.5 ECGs ................................................................................................................. 39
9.2.6 C-SSRS .............................................................................................................. 41
9.2.7 Study  Drug Administration ................................................................................ 41
9.2.8 AE Monitoring ................................................................................................... 42
TAK -831
TAK -831-1005 Page 4of 84
Protocol Incorporating Amendment No. 02 19 March 2018
CONFIDENTIAL9.2.9 Laboratory  Procedures and Assessments ............................................................ 42
9.3 PK, PD, and PGx, Samples ...................................................................................... 43
9.3.1 PK Measurements .............................................................................................. 44
9.3.2 PD Measurements .............................................................................................. 44
9.3.3 PGx Measurements ............................................................................................ 45
9.3.4 Total  Blood Vol ume........................................................................................... 45
9.3.5Confinement ...................................................................................................... 45
10.0 ADVERSE EVENTS .................................................................................................... 47
10.1 Definit ions and El ements of AEs ............................................................................. 47
10.1.1 SAEs .................................................................................................................. 49
10.1.2 Speci al Interest AEs ........................................................................................... 50
10.2 AE Procedures ......................................................................................................... 50
10.2.1 Assigning Severit y/Intensit y of AEs ................................................................... 50
10.2.2 Assigning Causalit y of AEs ................................................................................ 50
10.2.3 Start Date ........................................................................................................... 50
10.2.4 End Date ............................................................................................................ 51
10.2.5 Pattern of AE (Frequency) ................................................................................. 51
10.2.6 Action Taken Wit h Study  Treatm ent.................................................................. 51
10.2.7 Outcom e............................................................................................................ 51
10.2.8 Collect ion and Reporti ng of AEs, SAEs, Special Interest AEs, and Abnormal 
LFTs .................................................................................................................. 52
10.2.9 Safety Reporting to Invest igators, IRBs or IECs, and Regulatory  Authori ties.....54
11.0 STATISTICAL METHODS .......................................................................................... 55
11.1 Statistical and Analyt ical Plans ................................................................................ 55
11.1.1 Analysis Sets ...................................................................................................... 55
11.1.2 Analysis of Demography  and Other Baseline Characterist ics............................. 55
11.1.3 PK Analysis ....................................................................................................... 56
11.1.4 PD Analysis ....................................................................................................... 56
11.1.5 Safety Analysis .................................................................................................. 56
11.2 Interim Analysis and Criteria for Early Terminat ion................................................ 57
11.3 Determinat ion of Sample Size .................................................................................. 57
12.0 QUALITY CONTROL AND QUALITY ASSURANCE ............................................... 58
12.1 Study -Site Moni toring Visit s................................................................................... 58
12.2 Protocol  Deviat ions.................................................................................................. 58
12.3 Qualit y Assurance Audits and Regulatory  Agency  Inspect ions................................ 58
13.0 ETHICAL ASPECTS OF T HE STUDY ........................................................................ 59
TAK -831
TAK -831-1005 Page 5of 84
Protocol Incorporating Amendment No. 02 19 March 2018
CONFIDENTIAL13.1 IRB and/or IEC Approval ........................................................................................ 59
13.2 Subject Informat ion, Inform ed Consent, and Subject Authorizat ion......................... 60
13.3 Subject Confidentialit y............................................................................................ 61
13.4 Publicat ion, Di sclosure, and Clinical Trial Registration Policy .................................61
13.4.1 Publicat ion and Disclosure ................................................................................. 61
13.4.2 Clinical Trial Registration .................................................................................. 62
13.4.3 Clinical Trial Result s Disclosure ........................................................................ 62
13.5 Insurance and Co mpensation for Injury .................................................................... 62
14.0 ADMINISTRATIVE AND R EFERENCE INFORMATION ......................................... 63
14.1 Administrative Informat ion...................................................................................... 63
14.1.1 Study  Contact Informat ion................................................................................. 63
14.1.2 INVESTIGATOR AGREEMENT ...................................................................... 64
14.1.3 Study -Related Responsibilit ies........................................................................... 65
14.1.4 List of Abbreviat ions......................................................................................... 65
15.0 DAT A HANDLING AND RE CORDKEEPING ............................................................ 67
15.1 CRFs (El ectronic and Paper) .................................................................................... 67
15.2 Record Retention ..................................................................................................... 67
16.0 REFERENCES .............................................................................................................. 69
17.0 APPENDICES ............................................................................................................... 70
LIST OF IN -TEXT TABLES
Table 6.a Proposed Doses and Cohort Dose Escalat ion...................................................... 20
Table 6.b Exposure Margins .............................................................................................. 23
Table 7.a Prohibited Medications, Supplements, and Dietary  Products .............................. 31
Table 9.a Primary Specimen Collections ........................................................................... 43
Table 10.a Takeda Medically Significant AE List ................................................................ 49
LIST OF APPENDICES
Appendix A Responsibilit ies o f the Invest igator ..................................................................... 70
Appendix B Elements of the Subject Informed Consent ......................................................... 72
Appendix C Invest igator Consent to the Use of Personal Information .................................... 75
Appendix D Pregnancy and Contraception ............................................................................. 76
Appendix E Detailed Descript ion of Amendments to Text ..................................................... 80
TAK-831
TAK-831-1005 Page 6 of 84
Protocol Incorporating Amendment No. 02 19 March 2018
CONFIDENTIAL1.0 STUDY SUMMARY
Name of Sponsor:
Takeda Development Center Americas, Inc.
One Takeda ParkwayDeerfield, IL 60015Compound:
TAK-831
Study Identifier: TAK-831-1005 Phase: 1
Protocol Title: A Randomized, Investigator and Subject Blinded, Sponsor Unblinded, Placebo-Controlled, Phase 1 
Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Escalating Multiple Doses of TAK-831 in Healthy Subjects
Trial Design:
The study is an investigator and subject blinded, sponsor unblinded, placebo-controlled clinical study progressively 
assessing independent cohorts of healthy subjects to continue evaluation of the safety, tolerability, and pharmacokinetics (PK) of escalating multiple doses of TAK-831 at doses higher than those achieved in the initial multiple rising dos e study (TAK-831-1001). 
Up to 6 cohorts will be run either singly or in parallel as non- cerebrospinal fluid (CSF) cohorts with plasma analysis 
or CSF cohorts with CSF analysis in addition to plasma analysis to assess TAK-831 exposure and  
 levels in the central nervous system (CNS). After meeting all the selection criteria, there will be 8 subjects 
enrolled in each cohort. They will be randomized on Day 1 in a 1:3 ratio to receive placebo or TAK-831. 
In CSF cohorts, lumbar CSF samples will be collected through either a single lumbar puncture or an indwelling 
temporary catheter on 2 separate occasions. In CSF cohorts that use an indwelling temporary catheter on both occasions, the first collection will occur on Day 1 and the second on Day 16. In CSF cohorts where the predose CSF 
sample is collected through a single lumbar puncture, the firs t CSF sample will be collected on Day -1 prior to the start 
of  monitoring and the second collection will be ob tained through use of an indwelling temporary catheter 
on Day 16. If an indwelling temporary catheter is being used, it will collect serial CSF samples for 24 hours.
Subjects in each cohort will be confined during dosing and be kept in the study unit for 24 hours after the last dose for 
non-CSF cohorts and 48 hours after catheter removal in CSF cohorts. The total confinement period in non-CSF cohorts will be 19 days (Day -2 to Day 17), 20 days in CSF cohorts where an indwelling temporary catheter is being 
used on Day 1 and Day 16 (confinement from Day -1 to Day 19); and 21 days in CSF cohorts where CSF is collected through a single predose lumbar puncture on Day -1 and through an indwelling catheter on Day 16 (confinement from Day -2 to Day 19). Follow-up assessments will occur on Day 30 (±2) for all cohorts. An exception to these minimum 
confinement periods will be made if a determination is made to evaluate QT/QTc intervals for additional single doses of TAK-831 in non-CSF cohorts based on the established tolerated dose range.
Trial Primary Objective:
To evaluate the safety and tolerability of TAK-831 when administered as multiple oral doses at escalating dose levels 
in healthy subjects.
Secondary Objectives:
To evaluate the PK of TAK-831 when admin istered as multiple oral doses at escalating dose levels in healthy subjects. 
Trial Subject Population: Healthy male subjects and female subjects not of childbearing potential, aged 18 to 55 
years, inclusive.
Planned Number of Subjects:
Approximately 48 (8 per cohort, up to 6 cohorts)Planned Number of Sites:
1CCICCI
CCI
TAK -831
TAK -831-1005 Page 7of 84
Protocol Incorporating Amendment No. 02 19 March 2018
CONFIDENTIALDose Levels:
Starting dose TAK -831 600 mg (tablet T2 formulation, 
Cohort 1) and 800 mg (suspension formulation, 
Cohort 2) and matching placeboRoute of Administration:
Oral
Duration of Treatment:
One day for SD part (followed by evaluation for 2 
days) and then 14 day s for MD part.Planned Trial Duration :
Approximately 58 days for each cohort: screening 28 days, 
treatment and assessments including follow -up 30 day s 
(treatment Days 1 and 3 to 16; assessments Days 1 to 17 for 
non-CSF cohorts or 1 to 19 for CSF cohorts; follow -up: 
Day 30 [±2]). Maximum duration: approximately 348 days 
for 6 cohorts.
Main Criteria for Inclusion for Healthy Subjects:
Inorder to be eligible for participation, subjects must:
Be a healthy  adult male or female not of childbearing potential.
Be aged 18 to 55 years, inclusive, at the time of informed consent and first study drug dose.
Weigh at least 45 kg and has a body mass index between 18.0 and 30.0 kg/m2, inclusive at Screening.
Main Criteria for Exclusion for Healthy Subjects:
The subject must be excluded from participating in the study if the subject:
Has a known hypersensitivity to any component of the formulation of T AK-831.
Has a risk of suicide according to the investigator’s clinical judgment (eg, per Columbia –Suicide Severity Rating 
Scale), or has made a suicide attempt in the previous 6 months.
Additional Exclusion Criteria for Cohort(s) with CSF Collection:
The s ubject must be excluded from participating in the study if the subject:
Has had CSF collection performed within 30 days before Check -in (Day  -
1).
Has a known hypersensitivity to the anesthetic or its derivatives used during CSF collection, or any medicatio n 
used to prepare the area of lumbar puncture.
Has significant vertebral deformities (scoliosis or kyphosis) which, in the opinion of the investigator, may 
interfere with lumbar puncture procedure.
Has a history of clinically significant back pain and/or i njury.
Has local infection at the puncture site.
Has thrombocytopenia or other suspected bleeding tendencies noted before procedure.
Has developed signs and symptoms of spinal radiculopathy, including lower extremity pain and paresthesia.
Has any  focal neu rological deficit that might suggest an increase in intracranial pressure.
Has any abnormal finding on ophthalmological assessment/fundoscopy suggestive of raised intracranial pressure 
(ie, optic disc swelling/edema; (uncontrolled) hypertensive retinopathy ).
Suffers regularly from moderate to severe headaches requiring analgesics.
Subjects with lower spinal malformations (on physical examination or lumbar spine radiography), local spinal 
infection, or other abnormalities that would exclude lumbar puncture ( LP).
Main Criteria for Evaluation and Analyses:
Primary Endpoints
Primary  endpoints are the safety parameters of TAK -831 and will be assessed as follows:
1.Percentage of subjects who experience at least 1 treatment -emergent adverse event (TEAE).
TAK-831
TAK-831-1005 Page 8 of 84
Protocol Incorporating Amendment No. 02 19 March 2018
CONFIDENTIAL2. Percentage of subjects who meet the markedly abnormal criteria for safety laboratory tests at least once postdose.
3. Percentage of subjects who meet the markedly abnormal criteria for vital sign measurements at least once 
postdose.
4. Percentage of subjects who meet the markedly abnormal criteria for safety electrocardiogram (ECG) parameters 
at least once postdose.
Secondary Endpoints 
Secondary endpoints are the plasma PK parameters of TAK-831 and will be measured as follows:1. Maximum observed plasma concentration (C
max) (Day 1). 
2. Maximum observed steady-state plasma concentration during a dosing interval (Day 16). 
3. Time of first occurrence of C max(Days 1 and 16). 
4. Area under the plasma concentration-time curve during a dosing interval (Days 1 and 16).
Statistical Considerations:
Safety:
Adverse events will be presented in listings, and TEAEs will be summarized. Individual results of laboratory tests 
(hematology, chemistry, and urinalysis) will be listed and Baseline, postdose, and changes from Baseline to postdose laboratory data will be summarized. Individual results of vital signs will be listed and Baseline, postdose, and changes from Baseline in vital signs will be summarized. Individual results of quantitative ECG parameters from the 12-lead 
safety ECGs will be listed and Baseline, postdose, and changes from Baseline in quantitative ECG parameters will be 
summarized. All summaries will be performed by regimen for placebo, each TAK-831 dose level, and TAK-831 overall. Other safety measures (neurological examination a nd the ophthalmoscopic assessment of the fundus, physical 
examination findings and suicidality assessments [C-SSRS]) will be presented in data listings. 
PK Measures:
Concentrations of TAK-831 in plasma (all cohorts) and CSF (CSF Cohort[s]) will be summarized by dose, drug 
formulation, and day over each scheduled sampling time using descriptive statistics. Individual plasma concentration data versus time will be presented in a data listing. Plasma and CSF PK parameters, including dose-normalized C
max
and AUCs, will be summarized by dose, drug formulation, and day using descriptive statistics. Changes in the PK parameters from Day 1 to Day 16 will be assessed by summarizing the ratio of Day 16 to Day 1 by dose. Dose proportionality in plasma PK parameters (C
maxand AUCs) will be assessed graphically for Day 1 and Day 16 plasma 
concentrations. Additional analyses will be included as appropriate.
Biomarker Measures and Exploratory Endpoints:
Sample Size Justification:
The sample size chosen of 8 subjects for all cohorts (6 active:2 placebo) is considered to be sufficient for the 
determination of progression to the next cohort based on the safety and PK data. The sample size was not based on statistical power considerations.CCI
TAK-831
TAK-831-1005 Page 9 of 84
Protocol Incorporating Amendment No. 02 19 March 2018 
CONFIDENTIAL1.1 Protocol Amendment No. 02 Summary of Changes 
Rationale for Amendment No. 02This document describes the changes in reference to the protocol incorporating Amendment 
No. 02. The primary reason for this amendment is to revise the study procedures to enable cohorts 
that obtain  measurements as described in the previous protocol in addition to the 
collection of a baseline CSF sample on Day -1 through a single lumbar puncture and serial CSF 
sampling on Day 16. In addition, the drug supply management has been updated. Clarifications, 
inconsistencies, and minor grammatical, editorial, and formatting changes are included for 
clarification purposes only.
For specific description of text changes and where the changes are located, see  Appendix E.  
Changes in Amendment No. 02
1. Updated study design and procedures.
2. Updated clinical study material ma nagement.CCI
TAK -831
TAK -831-1005 Page 10of 84
Protocol Incorporating Amendment No. 02 19 March 2018 
CONFIDENTIAL2.0 STUDY SCHEMATIC
Cohorts
(up to 6 as 
needed)Pretreatment Period Treatment and Assessments (a)
Study ExitFollow -
up (b) ScreeningCheck -in/ 
BaselineSD Part
MD Part Treatment Evaluation
Non-CSF (or 
CSF cohorts 
that collect 
Day -1 CSF 
samples via a 
single predose 
lumbar 
puncture) Days -28 to -3 Day -2 Day 1 Days 1 to 2 Days 3 to 
16Day 17 (no n-CSF 
cohort) / Day 19 
(CSF cohort 
where Day  -1 
CSF is collected 
via a single 
predose lumbar 
puncture)Day 30 
(±2)
CSF Days -28 to -2 Day -1 Day 1 Days 1 to 2 Days 3 to 
16Day 19 Day 30 
(±2)
                                 Confinement                              
CSF=cerebrospinal fluid, MD=multiple dose, PD=pharmacodynamic, PK=pharmacodynamic, SD=single dose.
(a) TAK -831 dosing will be on Day 1 for SD and Days 3 through 16 for MD.
(b) The Follow -up Visit will occur by telephone unless abnormal, clinically signific ant findings are observed upon 
discharge. In these cases, subjects may then be brought back to the clinic for re -evaluation per investigator’s 
discretio n. 
TAK -831
TAK -831-1005 Page 11of 84
Protocol Incorporating Amendment No. 02 19 March 2018
CONFIDENTIAL3.0 SCHEDULE OF STUDY PROCEDURES
Study Day:Scr-
een-i
ngCheck in / Baseline 
AssessmentsTreatment Day Study 
Exit (a)
Early 
Termina -
tion
(b)Follow -
up
-28 
to -3Day -2 (non -CSF or 
CSF cohorts) that 
collect baseline CSF 
samples via a single 
predose lumbar 
puncture or Day -1 
(CSF cohorts) 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16Day 17 
(non -C
SF) / 
Day 19 
(CSF)30
(±2) (c)
ADMINISTRATIVE PROCEDURES
Informed consent X
Inclusion/exclusion 
criteriaX X X
Demographics/ medical 
historyX
Medication history X X
Concurrent medical 
conditio nsX X
CLINICAL PROCEDURES/ASSESSMENTS
Full physical 
examinationX X X X (X)
Height X
Weight and BMI (d) X X X (X)
Concomitant 
medications (e)X X X X XXXXXXXXXXXXXX X X X
Vital signs (f) X X X X XXXXXXXXXXXXXX X X (X)
Neurological 
examination and 
fundoscopy (g)X X
Lumbar spine 
radiography  (for CSF 
cohorts only) (h) X
TAK-831
TAK-831-1005 Page 12 of 84
Protocol Incorporating Amendment No. 02 19 March 2018
CONFIDENTIALStudy Day:Scr-
een-i
ngCheck in / Baseline 
AssessmentsTreatment Day Study 
Exit (a)
Early 
Termina-
tion
(b)Follow-
up
-28 
to -3Day -2 (non-CSF or 
CSF cohorts) that 
collect baseline CSF 
samples via a single 
predose lumbar 
puncture or Day -1 
( C S F c o h o r t s ) 1 2 3456789 1 0 1 1 1 2 1 3 1 4 1 5 1 6Day 17 
(non-C
SF) / 
Day 19 
(CSF)30
(±2) (c)
Safety ECG (i) XXX X X X X ( X )
C-SSRS (k) XX XX
Study drug 
administrationX XXXXXXXXXXXXXX
A E  a s s e s s m e n t  X X X XXXXXXXXXXXXXX X X X
LABORATORY PROCEDURES
Clinical laboratory tests 
(l)XXX X X X ( X )
Hepatitis panel (HBsAg 
and anti-HCV)X
HIV screen X
FSH (m) X
hCG (n) X X XX ( X )
Hormone laboratory 
tests (o)XX X ( X )
Drug screen X X
PGx EVALUATIONS
DNA sample collection 
(p)X
PK EVALUATIONS
PK blood collection (q) X X X X X X
PK CSF collection (r) X (r) X (r) X (r) XCCI
TAK-831
TAK-831-1005 Page 13 of 84
Protocol Incorporating Amendment No. 02 19 March 2018
CONFIDENTIALStudy Day:Scr-
een-i
ngCheck in / Baseline 
AssessmentsTreatment Day Study 
Exit (a)
Early 
Termina-
tion
(b)Follow-
up
-28 
to -3Day -2 (non-CSF or 
CSF cohorts) that 
collect baseline CSF 
samples via a single 
predose lumbar 
puncture or Day -1 
( C S F c o h o r t s ) 1 2 3456789 1 0 1 1 1 2 1 3 1 4 1 5 1 6Day 17 
(non-C
SF) / 
Day 19 
(CSF)30
(±2) (c)
PD/BIOMARKER EVALUATIONS
AE=adverse event, anti-HCV=antibody to hepatitis C virus, BMI=body mass index, C-SSRS=Columbia–Suicide Severity Rating Scale, E CG=electrocardiogram, 
FSH=follicle-stimulating hormone, HbA1c=glycosylated hemoglobin, HBsAg=hepatitis B surface antigen, hCG=human chorionic gonadot ropin, HIV=human 
immunodeficiency syndrome, PGx=pharmacogenomics, TSH=thyrotropin.
(a) Study exit for non-CSF cohorts occurs on Day 17 and for CSF cohorts on Day 19.(b) At Early Termination, perform all procedures per Section  7.6.
(c) The Follow-up Visit will occur by telephone on Day 30 (±2) unless abnormal, clinically significant findings are observed up on discharge. In these cases, subjects 
must be brought back to the clinic for re-evaluation per investigator’s discretion. (X) is for optional procedure.(d) BMI will be calculated only at Screening.(e) Record all ongoing medications from Screening and throughout the study.(f) Vital signs (oral temperature, respiratory rate, pulse, and blood pressure) will be obtained at Screening, Check-in, Day 1, and Days 3 through 16 at predose 
(within 60 minutes before dosing) and at 1, 4, and 12 hours after the morning dose, and Study Exit/Early Termination and as appr opriate at the Follow-up Visit. Day 
2 vital signs should be collected approximately 24 hours after the Day 1 dose is administered. Pulse and blood pressure will be  measured after 5 minutes supine and 
again at 1 and 3 minutes after standing for all scheduled time poi nts, with exception of Day 1, Day 2, and Day 16 in cohorts wh ere CSF collection is performed using 
an indwelling catheter, when only supine measurements will be taken. 
(g) Only for CSF cohorts: A neurological assessment and eye examination (ophthalmological assessment of the retina, fundoscopy)  will be performed on Day -2 
(baseline collection through single lumbar puncture), Day -1 (baseline collection through indwelling catheter) and Day 15. (h) Lumbar spine radiography (for CSF cohorts only) if one has not been performed within the past 12 months prior to the screen ing visit. 
(i) A standard 12-lead ECG (single) will be recorded at Screening, Check-in, Day 1 (predose [within 60 minutes prior to dosing] , and at 1.5 hour postdose (morning 
dose), Day 16 (predose [within 60 minutes prior to dosing], and at 1 and 2 hours after morning dose, Day 10 (predose), and Stud y Exit/Early Termination and as 
appropriate at the Follow-up Visit.CCICCI
CCI
TAK-831
TAK-831-1005 Page 14 of 84
Protocol Incorporating Amendment No. 02 19 March 2018
CONFIDENTIAL(k) The C-SSRS (Lifetime/Recent) will be administered at Screening; the C-SSRS (since last visit) will be administered at Check -in and at Study Exit/Early 
Termination.(l) Clinical laboratory tests (hematology, serum chemistry, and urinalysis) will be collected at Screening, Check-in, and after  a 10-hour fast at predose on Days 1, 
10, and at Study Exit/Early Termination and as appropriate at the Follow-up Visit. 
(m) For women only: A FSH level will be obtained on postmenopausal women at Screening only. (n) For women only: Serum hCG will be performed at Screeni ng, Day -1, and Study Exit/Early Termination, and at the Follow-up Vi sit if the subject is brought back 
to the clinic for re-evaluation.(o) Hormone laboratory tests (prolactin, growth hormone, cortisol, and TSH) will be collected on Day 1 (before dosing, under fa sted conditions and 3 hours 
postdose) and at Study Exit/Early Termination (morning values, under fasted conditions) and as appropriate at the Follow-up Vis it.
(p) One blood sample (6 mL) will be collected for DNA analysis before dosing on Day 1.(q) Blood samples (4 mL) for PK analyses will be collected on Day 1 (within 30 minutes before dosing) and at 0.5, 1, 1.5, 2, 4,  8, 12, 24, hours after the morning 
dose; on Day 10 (predose), Day 13 (predose), and on Day 16 at predose (within 30 minutes before dosing), and at 0.5, 1, 2, 4, 8,  12, 16, and 24 hours after the 
morning dose and at Early Termination. 
CCICCICCI
TAK-831
TAK-831-1005 Page 15 of 84
Protocol Incorporating Amendment No. 02 19 March 2018
CONFIDENTIAL4.0 INTRODUCTION
4.1 Background
Inhibition of D- amino acid oxidase (DAO) has been proposed as a potential for the treatment of 
schizophrenia. DAO is a peroxisomal enzyme active toward neutral D-amino acids, which is 
expressed in both the periphery and the brai n. DAO degrades D-amino acids by oxidation. In the 
periphery, this action likely plays a role in th e detoxification of D-amino acids from bacterial and 
other sources, as amino acids used for protein synthesis and other metabolic processes are L-amino 
acids. Few D- amino acids are known to play a biologi cal role in humans, but D-serine in the brain 
has been connected to the regulation of glutamatergic neurotransmission [1], and D-serine has 
been shown to be an obligatory co-agonist of N-methyl- D-aspartate (NMDA)-type glutamate 
receptors, binding to the glycine site. Inhibition of DAO elevates endogenous D-serine in the 
cerebellum, increasing Purkinje cell long term depression via activation of δ2 glutamate receptor 
and/or NMDA receptors with subsequent internalization of AMPA 
(α-amino-3- hydroxy-5-methyl-4-isoxazole propionic acid)-type glutamate receptors [2].
Hypofunction of NMDA receptors is considered a possible mechanism in the pathophysiology of 
schizophrenia, which could be mitigated by increasing D-serine levels in the brain [3]. Changes in 
D-serine levels or in the ratio of D-serine to total serine have been reported in the plasma of 
patients with schizophrenia, both naive and under drug treatment [4-7] . In addition, serine 
racemase (the D-serine generating enzyme) and the NMDA NR2A subunit are among the risk 
genes identified from the recent large scale genome-wide association study analysis, indicating the 
biological relevance to schizophrenia of the genetic pathway in which DAO sits [8].
Adding to the above evidence of a potential role of DAO in the pathophysiology  of schizophrenia, 
a weak inhibitor of DAO, sodium benzoate, demonstrated efficacy in positive, negative, and 
cognitive symptoms in a proof-of-concept study in subjects with schizophrenia [9].
While current medications mitigate positive symptoms of schizophrenia and to some extent the 
negative symptoms, cognitive impairment repres ents an area of unmet medical need. Moreover, 
cognitive and negative symptoms are associated with functional outcomes to a greater degree than 
positive symptoms and remain an area of foc us for the development of novel therapeutics.
4.2 Rationale for the Proposed Study
TAK-831 is a highly selective and potent inhibitor of DAO. TAK-831 was shown to increase 
D-serine levels in the cerebellum of normal r ats, and it also demonstrated a positive effect on 
cognition and social interaction in rodent c ognition and behavioral models. TAK- 831 is under 
development for the treatment of negative symptoms of schizophrenia (NSS) and cognitive 
impairment associated with schizophrenia (CIAS), as well as for cerebellar ataxias such as 
Friedreich ataxia. In addition to safety and to lerability, the current proposed study is aimed at 
providing information on the relationship between concentrations of TAK-831 
 CCI
TAK -831
TAK -831-1005 Page 16of 84
Protocol Incorporating Amendment No. 02 19 March 2018
CONFIDENTIAL4.3 Benefit/Risk Profile
There i s no benefit to subjects in this clinical study.
The fo llowing ri sk mit igation measures will be implemented in this study  with TAK -831. Th ese 
measures are based on what is known about the mechanism o f action of  TAK -831, nonclinical 
data, and the 2 phase 1 studies conducted to date. Procedures may  be added during the study  if 
necessary  based on evaluat ion of any  addi tional clinical or nonclin ical safet y data.
TAK -831 has been used in a prior single dose (up to 750 mg in oral suspensio n and 100 mg in 
tablet T1 formulat ion and 14 days mult iple dose (up to 400 mg QD in oral suspensio n) study in 
healt hy subjects (TAK -831- 1001) with good safet y and tolerabili ty, as well  as a single dose 
PET study  (TAK -831- 1003), and these studies have not resulted in a safet y signal that would 
prevent addit ional studies. Addit ionally, a T2 tablet formulat ion is currently under assessment 
in a single dose food effect study  (TAK -831- 1004) that will contribute addit ional data to 
inform  dose sel ection during the conduct of this study .
Acute hypersensit ivity/anaphylact ic reactions to new chemical entit ies are al ways a possible 
risk in any clinical study . Appropri ate proce dures should be used to manage such possible 
risks.
Study  procedure –specific risks include issues relat ing to blood collection for safet y 
assessment/PK and PD monitoring (venipuncture may cause bruising), and the placement of 
ECG pads, which may  cause som elocal redness and/or ery thema/i tching. 
The risk of pain or disco mfort at the site of CSF collect ion and the risk of headache in cohorts 
where CSF will be co llected for PK and PD assessment. Severe headaches may require a blood 
patch procedure. There is a small risk of infection with indwelling catheters.
The invest igator has discretion to use his/her clinical judgment as to whether to allow a subject 
to proceed in the study or whether to unblind the subject in order to determine his/her treatment 
allocat i
on.
The C-SSRS will be administered to monitor emergent suicidalit y.
TAK-831
TAK-831-1005 Page 17 of 84
Protocol Incorporating Amendment No. 02 19 March 2018
CONFIDENTIAL5.0 TRIAL OBJECTIVES AND ENDPOINTS
5.1 Trial Objectives
5.1.1 Trial Primary Objective
To evaluate the safety and tolerability of TAK-831 when administered as multiple oral doses at 
escalating dose levels in healthy subjects.
5.1.2 Trial Secondary Objective
To evaluate the PK of TAK-831 when administered as multiple oral doses at escalating dose levels 
in healthy subjects.
5.1.3 Trial Exploratory Objectives
5.2 Endpoints
5.2.1 Primary Endpoints
Primary endpoints are the safety parameters of TAK-831 and will be assessed as follows:1. Percentage of subjects who experience at least 1 treatment-emergent adverse event (TEAE)
2. Percentage of subjects who meet the markedly abnormal criteria for safety laboratory tests at 
least once postdose.
3. Percentage of subjects who meet the markedly abnormal criteria for vital sign measurements at 
least once postdose.
4. Percentage of subjects who meet the markedly abnormal criteria for safety ECG parameters at 
least once postdose.
5.2.2 Secondary Endpoints 
Secondary endpoints are the plasma PK parameters of TAK-831 and will be measured as follows:
1. Maximum observed plasma concentration (C
max) (Day 1). 
2. Maximum observed steady-state plasma concentration during a dosing interval (Day 16). CCI
TAK-831
TAK-831-1005 Page 18 of 84
Protocol Incorporating Amendment No. 02 19 March 2018
CONFIDENTIAL3. Time of first occurrence of C max(Days 1 and 16). 
4. Area under the plasma concentration-time curve during a dosing interval (Days 1 and 16). 
5.2.3 Exploratory Endpoints
CCI
TAK-831
TAK-831-1005 Page 19 of 84
Protocol Incorporating Amendment No. 02 19 March 2018
CONFIDENTIAL6.0 TRIAL DESIGN AND DESCRIPTION
6.1 Trial Design 
The study is an investigator and subject blinde d, sponsor unblinded, placebo-controlled clinical 
study progressively assessing independent cohorts of h ealthy sub jects to continue evaluation of the 
safety, tolerability, and PK of escalating single doses (SD) and multiple doses (MD) of TAK- 831, 
as either a suspension or T2 tablet formulation, at levels higher than those achieved in the init ial 
single and multiple rising dose (SRD/MRD) Study TAK-831-1001. 
Up to 6 cohorts will be run either singly or in parallel as non- cerebrospinal fluid (CSF) cohorts 
with plasma analysis or CSF cohorts with CSF analysis in addition to plasma analysis to assess 
TAK-831 exposure and  levels in the central nervous system (CNS). 
After meeting all the selection criteria, there will be 8 subjects enrolled in each cohort. They will 
be randomized on Day 1 in a 1:3 ratio to receive placebo or TAK-831. 
All cohorts will start with an initial, in-house SD period to include predose PD assessments on 
Day -1, Day 1 TAK-831 dosing, and a 48-hour in-house observation period with full PK 
collections. The SD PK collection and observation phase will be followed by 14 days of in-house 
MD.
In CSF cohorts, lumbar CSF samples will be collected through either a single lumbar puncture or 
an indwelling temporary catheter on 2 separate o ccasions. In CSF cohorts that use an indwelling 
temporary catheter on both occasions, the first collection will occur on Day 1, and the second on 
Day 16. In CSF cohorts where the pre-dose CSF sample is collected through a single lumbar 
puncture, the first CSF sample will be collected on Day -1 prior to the start of  
monitoring and the second collection will be obtained through use of an indwelling temporary 
catheter on Day 16. If an indwelling temporary catheter  is being used, it will collect serial CSF 
samples for 24 hours.
Subjects in each cohort will be confined during dosing and be kept in the study unit for 24 hours 
after the last dose for non-CSF cohorts and 48 hours after catheter removal in CSF cohorts. The 
total confinement period in non-CSF cohorts will be 19 days (Day -2 to Day 17), 20 days in CSF 
cohorts where an indwelling temporary catheter is  being used on Day 1 and Day 16 (confinement 
from Day -1 to Day 19); and 21 days in CSF cohorts where CSF is collected through a single 
predose lumbar puncture on Day -1 prior to the start of  and through an 
indwelling catheter on Day 16 (confinement from Day -2 to Day 19). Follow-up assessments will 
occur on Day 30 (±2) for all cohorts. An exception to  these minimum confinement periods will be 
made if a determination is made to evaluate QT/QTc intervals for additional single doses of 
TAK-831 in non-CSF cohorts based on the established tolerated dose range.CCI
CCICCICCI
TAK-831
TAK-831-1005 Page 20 of 84
Protocol Incorporating Amendment No. 02 19 March 2018
CONFIDENTIALThe Study Schematic and Schedule of Study Procedures are provided in Section  2.0and 
Section 3.0, respectively.
6.2 Dose Escalation
In Cohort 1, the proposed starting dose is TAK-831 600 mg QD, administered as a tablet 
formulation (Formulation T2) and, in Cohort 2, the starting dose is TAK-831 800 mg QD 
administered as a suspension formu lation. Cohort 1 and Cohort 2 will run in parallel.
The proposed dose and dose escalation is provided in  Table 6.a.
Table 6.a Proposed Doses and Cohort Dose Escalation
CohortProposed 
Dose, 
(Estimated) Formulation Rationale
1 (with CSF) 600 mg/day 
(QD)Tablet 
formulation T2T2 tablet formulation at 600 mg is expected to deliver 
exposures comparable to 400 mg administered as a suspension. This exposure level demonstrated acceptable safety and tolerability with multiple dosing 
in Study T AK-831- 1001;  
 
2 (with CSF) 800 mg/day 
(QD)Suspension 
formulation Cohort 2 w ill be run in parallel with Cohort 1. TAK-831 
750 mg single dose administered as a suspension was found to have acceptable tolerability in Study TAK-831-1001. The highest multiple dose level in that study was 400 mg suspension.  
 
3 1200 mg/day 
(a) Suspension Evaluate safety, tolerability, PK and PD effects of 
increased doses of TAK-831 administered as a suspension as tolerated up to the maximum exposure defined below. Once this objective is met, possible additional doses and dose regimens (eg, BID, single doses), with or without CSF collections and  (in non-CSF cohorts or in CSF cohorts where Day -1 
CSF is being collected through a single lumbar 
puncture), will be examined, pending PK-PD results of 
Cohorts 1 and 2.4 (with CSF) 100 mg/day 
(a)Tablet 
formulation T2
5 (with CSF where Day -1 
CSF is collected through 
a single lumbar puncture)15 mg Suspension
6 TBD (a) Tablet 
formulation T2 
or suspension
TBD=to be determined. 
(a) No selected dose will have exposures projected to exceed the study exposure limits or a maximum 2000 mg dose, whichever is lower.CCI
CCI
CCICCI
TAK -831
TAK -831-1005 Page 21of 84
Protocol Incorporating Amendment No. 02 19 March 2018
CONFIDENTIALExposure levels in each cohort will be mo nitored closely and will not exceed exposures seen at the 
end of a 13- week repeat dose toxicit y studies in monkeys (see Section 6.3.2 ). 
Since, the highest dose tested in single rising dose portion of Study  TAK -831- 1001 w as 750 mg 
administered as a suspensio n, all dose levels above 750 mg/day will be tested first in SD setting 
before MD in subsequent cohorts.
All decisio ns concerning dose escalat ion will be made by Takeda (at a minimum, the clinical 
science representative[ s], quant itative clinical pharmaco logist, study  stati stician and 
pharmacovigilance physician) and the principal investigator. The invest igator and subjects will 
remain blinded throughout the study , but at the complet ion of each cohort, specific Takeda 
personnel listed in associated study  docum entati on may  be unblinded to analyze data considered 
necessary  to determine subsequent doses and cohort management decisions. All data presentations 
prepared for discussions with the invest igator and site staff will co ntain only blinded study  data, 
except in the event that formal study unblinding procedures detailed in Protocol Section 8.1.5 have 
been fo llowed and discussio n of related data i s requi red.
If agreement regarding a dose escalat ion decisio n cannot be reached between the principal 
investigator and Takeda, the study  will be stopped.
Based on emerging safet y and tol erabilit y and PK data, the planned dose levels may  be m odified.
All adverse events reported during the Treatment Period, both within and across cohorts, up to the 
time of discharge will be evaluated to assess the need for subject and/or study  terminat ion in 
accordance with the prespecified criteria for discont inuation/terminat ion (Section 6.5).
Following assessment of the adverse event data and predefined criteria for study terminat ion, dose 
escalat ion may be interrupted/ stopped if these criteria are met. Based on review of study  data as 
outlined above , Takeda, in consultat ion with the principal invest
igator, will decide if and how it is 
appropriate for the study  to proceed. 
Dose escalat ion may be interrupted/stopped if:
Exposures in any cohort exceed those observed at the top dose tested in the monkey toxicit y 
study , that i s, a m ean C maxof 3680 ng/mL or a m ean AUC 24of 35,700 hr*ng/mL. 
The exposures reach the plasma exposure plateau in the 2 highest dose cohorts.
One or more subjects in any single cohort or across more than 1 cohort experience an SAE or 2 
severe or clinically significant AEs occur that are considered related to study  drug.
One or m ore subjects in any single cohort or across more than 1 cohort experience severe 
psychiatric symptoms, including any level o f treatment -emergent suicidal ideat ion* that are 
considered related to study  drug.
[*Treatm ent-emergent sui cidali ty com pared to Baseline, as measured by an increase in 
suicidal ideation or behavior categor y (on the C -SSRS) during treatment fro m the maximum 
suicidal ideation/behavior category  at Baseline, or any suicidal ideat ion/behavior during 
treatm ent if there was none at Baseline].
TAK-831
TAK-831-1005 Page 22 of 84
Protocol Incorporating Amendment No. 02 19 March 2018
CONFIDENTIAL6.3 Rationale for Trial Design, Dose, and Endpoints
6.3.1 Rationale of Trial Design 
In addition to assessing safety, tolerabilit y, and PK of TAK-831, the proposed study is aimed at 
providing information on the relationship between concentrations of TAK-831 and  
 to be explored in both plasma and CSF in healthy subjects in order to support dose 
selection for the follow-up studies planned to evaluate PD effects of TAK-831 in subjects with 
schizophrenia. assessments will be conducted in non-CSF cohorts for 
exposure-response analysis of ECG parameters, or in CSF cohorts where the first CSF sample is 
collected through single lumbar puncture prior to the start of on Day -1.
6.3.2 Rationale for Dose 
Based on the results of toxicology studies, the m onkey is considered the more sensitive species. 
The NOAEL in the 13-week repeat dose study was based on adverse findings of vomiting, 
diarrhea, and loose stool at the top dose of 600 mg /kg/day. Therefore, the next lower dose tested, 
100 mg/kg/day, was assigned the NOAEL for both sexe s. This NOAEL was as sociated with mean 
Cmaxvalues of 1340 and 1270 ng/mL and mean AUC 24values of 7490 and 9190 h*ng/mL for 
males and females, respectively, on Day 91.
As the adverse effects of treatment in the monkey (vomiting, diarrhea, and loose stool) are easily 
monitored in humans, exceeding the NOAEL of 100 mg/kg/day in monkeys may be warranted in 
order to achieve adequate CNS exposures in humans. The targeted maximum exposure in humans 
is that attained in monkeys at 600 mg/kg/day. Dose escalation will be stopped if significant 
vomiting or diarrhea is observed in humans. In monkeys, at 600 mg/kg/day (dosed as 300 mg/kg, 
BID), respective mean C maxand AUC 24values on Day 91 were 3680 ng/mL and 35,700 h*ng/mL, 
sexes combined.
The highest dose tested in the MRD portion of Study TAK-831-1001 was 400 mg daily of the oral 
suspension formulation for 14 days. At this dose level, there were no significant adverse effects 
reported, and C maxexposures had reached those of female monkey at the NOAEL dose (C max
1270 ng/mL and AUC 243454 h*ng/mL) (Table 6.b) . CCI
CCICCI
TAK-831
TAK-831-1005 Page 23 of 84
Protocol Incorporating Amendment No. 02 19 March 2018
CONFIDENTIALTable 6.b Exposure Margins
Species-StudyDose 
(mg/kg/day or mg)Cmax
(ng/mL)AUC 24
(h*ng/mL)Margin (a)
Cmax AUC 24
Rat 13-week(Day 91)1000
(NOAEL)11,000 (M)
26,100 (F)162,000 (M)
355,000 (F)8.7 (M)
20.6 (F)46.9 (M)
102.8 (F)
Monkey 13-week(Day 91)100 (50 BID)
(NOAEL)1340 (M)
1270 (F)7490 (M)
9190 (F)1 (M)
1 (F)2.2 (M)
2.7 (F)
600 (300 BID)(vomiting, diarrhea)4650 (M)
2710 (F)45,500 (M)
25,900 (F)3.7 (M)
2.1 (F)13.2 (M)
7.5 (F)
Human MRD(Day 14)400 mg QD
(suspension form)1270 (M) 3454 (M) - -
F=female, M=male.
(a) Margins relative to Day 14 exposures in humans administered 400 mg/day.
Based on these data, the proposed doses in the current study are as follows:
Cohort 1 subjects will receive a starting dose of TAK-831 600 mg QD as a T2 tablet formulation, 
which is expected to achieve geometric mean TAK-831 C maxand AUC 24about 60% and 83%, 
respectively of that of 400 mg suspension formulation under fasted conditions.
In parallel to Cohort 1, Cohort 2 will test the su spension formulatio n with 800 mg dose. 
Subsequent cohorts will have dose escalated as tolerable. Dose escalation will be stopped 
according to the stopping rules detailed in Section  6.2.
Proposed dose levels as well as dosing intervals for the subsequent cohorts may be adjusted after 
reviewing safety, tolerability, PK, and/or PD data of Cohorts 1 and 2.
6.3.3 Rationale for Endpoints
6.3.3.1 Primary Endpoint
The primary endpoint for this trial is the composite of safety variables to determine the safety and 
tolerability of oral multiple doses of TAK-831, and dose- limiting eff ects of TAK-831 and are 
common for this type of study.
6.3.3.2 Secondary Endpoint
The secondary endpoints consist of standard plasma PK variables to determine drug exposure at 
each dose to facilitate dose escalation.
6.3.3.3 Exploratory Endpoints
CCI
TAK-831
TAK-831-1005 Page 24 of 84
Protocol Incorporating Amendment No. 02 19 March 2018
CONFIDENTIAL6.3.4 Critical Procedures Bas ed on Trial Objectives: Timing of Procedures
For this trial, collecting safety data and collecting blood in all cohorts and CSF samples in one or 
more cohorts for TAK-831 PK and PD are the critical procedures. 
!At any postdose time point, safety data need should be collected as close to the exact time point 
as possible.
!At any postdose time point, the blood and/or C SF sample for TAK-831 PK, and PD needs to be 
collected as close to the exact time point as possible.
!All other procedures should be completed as close as possible, either before or after the 
prescribed/scheduled time.
!The order of priority can be changed during the trial with joint agreement of the investigator 
and the sponsor.
Any nonscheduled procedures required for urgent evaluation of safety concerns take precedence 
over all routine scheduled procedures.
6.4 Trial Design/Dosing/Procedures Modifications Permitted Within Protocol 
Parameters
This is a phase 1 assessment of TAK-831 in healthy subjects. The PK, PD, and safety profiles of 
the compound are still being elucidated. This protocol is written with some flexibility to 
accommodate the inherent dynamic nature of phase 1 dose rising trials. Modifications to the dose, 
dosing regimen, and/or clinical or laboratory procedures currently outlined in Section  6.1and 6.2
may be required to achieve the trial objectives and to ensure the safety of the trial subjects.
Some alterations from the currently outlined dose and/or dosing regimen may be permitted based 
on newly available data, but the maximum daily dose/exposure detailed in Section  6.3.2,  may not 
exceed those currently outlined.
!Additional cohorts may be added.
!Repeat of or decrease in the dose of the trial drug administered.
!Entire cohorts may be omitted.
!Increase/decrease in the duration of trial drug administration (eg, number of days), including 
evaluation of single doses of TAK-831 on QT/QTc in tervals based on the established tolerated 
dose range.
!Adjustment of the dosing interval, for example, divided doses BID to QD, QD to BID, 3 times 
daily, or vice versa.CCI
TAK-831
TAK-831-1005 Page 25 of 84
Protocol Incorporating Amendment No. 02 19 March 2018
CONFIDENTIAL!A planned PK data review may be eliminated if agreed to by the sponsor and investigator and if 
no further increases in total daily dose occur. 
!Addition of a PK data review.
!Instructions to take trial drug with or without food or drink may also be modified based on 
newly available data (ie, food effect is known).
!The planned CSF sample may be eliminated, if agreed to by the sponsor and the investigator.
The PK/PD sampling scheme currently outlined in the protocol may be modified during the trial 
based on newly available PK or PD data (eg, to obtain data closer to the time of peak plasma 
concentrations).  
.
Up to an additional 50 mL of blood may be drawn for PK and/or biomarker analyses. This may 
include repeat samples or modified PK/PD time points based on emerging data. The total blood 
volume withdrawn from any single subject will not exceed the maximum allowable volume during 
his/her participation in the entire trial.
The timing of planned procedures for assessment of safe ty procedures (eg, vital signs, ECG, safety 
laboratory tests) currently outlined in the protocol may be modified during the trial based on newly 
available safety, tolerability, PK, or PK/PD data (eg, to obtain data closer to the time of peak 
plasma concentrations). These changes will not increase the number of trial procedures for a given 
subject during his/her participation in the entire trial.
Additional laboratory safety tests may be adde d to blood samples previously drawn to obtain 
additional safety information (eg, adding creatine kinase to serum chemistry panel that was 
already drawn).
It is understood that the current trial may employ some or none of the alterations described above. 
Any alteration made to this protocol to meet the trial objectives must be detailed by the sponsor in 
a letter to the Trial File and forwarded to the investigator for retention. The letter may be 
forwarded to the institutional review board (IRB)/independent ethics committee (IEC) at the 
discretion of the investigator.
6.5 Trial Beginning and End/Completion
6.5.1 Definition of Begi nning of the Trial
The overall trial begins when the first subject signs the trial informed consent form.
6.5.2 Definition of End of the Trial
The overall trial ends when the last subject completes the last planned or Follow-up 
Visit/interaction associated with a planned visit (this can be a phone contact), discontinues from 
the trial, or is lost to follow-up (ie, the inves tigator is unable to contact the subject); or dosing of 
future cohorts is stopped based on the dose escalation rules.CCI
TAK -831
TAK -831-1005 Page 26of 84
Protocol Incorporating Amendment No. 02 19 March 2018
CONFIDENTIAL6.5.3 Definition of Trial Completion
The pr imary object ive of this phase 1 trial is to ident ify safet y and tol erabili ty of multiple rising 
doses. Therefore, it is possible that not all planned doses to be administered, if this object ive is 
achieved at lower dose levels in this trial. This is not co nsidered an early terminat ion of the trial, 
but rather an earlier than ant icipated achievement of the trial object ive(s) or trial complet ion. 
Therefore, the definit ion of tri al com pletion follows the sam e rules as definit ion of end of trial 
(Secti on 6.5.2 ) for the dosing group achieving the primary object ive.
6.5.4 Definition of Trial Discontinuation
Trial discont inuat ion because of nonsafet y reasons , such as:
A finding ( eg, PK, PD, efficacy, bio logic targets) from another nonclinical or clinical trial 
using the trial treatment(s) results in the trial being stopped for a non –safet y-related reason.
Data from co mparator(s), drug(s) of the same class, or methodology(ies) used in this trial 
beco me available and results in the trial being stopped for a non –safet y
-related reason.
The tri al is stopped because of nonscientific and nonsafet y reasons, such as slow enrollment.
Trial discont inuat ion because of safet yreasons:
Early tri al terminat ion because of unant icipated concerns o f safety  to the trial  subjects arising 
from no nclinical or clinical trials wit h the trial treatment(s), comparator(s), drug(s) of the same 
class, or m ethodol ogy(ies) used in this trial.
6.5.5 Criteria for Prematu re Termination or Suspension of the Trial
6.5.5.1 Criteria for Premature Termination or Suspension of Trial
The study  will be co mpleted as planned unless 1 or more of the fo llowing criteria are satisfied that 
requi re tem porary  suspensi on or early  terminat ion of th e study .
New informat ion or other evaluat ion regarding the safet y or efficacy  of the study  medicat ion 
that indicates a change in the known risk/benefit profile for the compound, such that the risk is 
no longer acceptable for subjects participat ing in the s tudy.
Significant vio lation of Good Clinical Practice (GCP) that compromises the ability to achieve 
the primary  study  objectives or compromises subject safet y.
Meet ing study -specific criteria for terminating the study  (eg, study  meets predefined rule for 
futilit y or benefit, study  meets predefined stopping rules within or between cohorts per 
Secti on6.2).
Two or more subjects in any  single cohort or across more than 1 cohort experience alanine 
aminotransferase (ALT) and/or aspartate aminotransferase (AST) elevat ions >5 times the 
upper limit of normal (ULN) in the absence of a conco mitant bilirubin increase (see point 
3 below)*. If 2 subjects in 1 dose level after dosing show the fo llowing findings in 2 
consecut ive measurements within 24 hours:
TAK -831
TAK -831-1005 Page 27of 84
Protocol Incorporating Amendment No. 02 19 March 2018
CONFIDENTIALALT or AST ≥3×ULN, or
ALT or AST ≥2×ULN and ALT or AST ≥5×baseline value, or
Total  bilirubin ≥2×ULN or
International normalized ratio (INR) >1.5 or
ALT and/or AS T elevations >3×ULN wit h the appearance of fat igue, nausea, vo miting, right 
upper quadrant pain or tenderness, fever, rash and/or eosinophilia (>5%) without findings of 
cholestasis or other alternate etio logy to expl ain the el evations (ie, “Hy’s Law cases” ).
*Please note that the study  may be terminated early  before full attainment of these criteria (eg, if 
just 1 subject experiences 1 of these events) if warranted by safet y data from  the other subjects 
dosed in the study  to date.
6.5.6 Criteria for Premature Ter mination or Suspension of a Site
A trial site may  be terminated prem aturely  or suspended if the site (including the invest igator) is 
found in significant vio lation of GCP, protocol, or contractual agreement, is unable to ensure 
adequate performance of the trial, or as otherwise permitted by  the contractual  agreement.
6.5.7 Procedures for Premature Termination or Suspension of the Study or a Site
If the sponsor, an IRB, or regulatory  authori ty elects to terminate or suspend the trial or the 
participat ion of an inv estigational site, a trial -specific procedure for early terminat ion or 
suspension will be provided by the sponsor; the procedure will be fo llowed by  applicable 
investigat ional sites during the course of termination or trial suspensio n.
TAK -831
TAK -831-1005 Page 28of 84
Protocol Incorporating Amendment No. 02 19 March 2018
CONFIDENTIAL7.0 SELECTION AND DISCONTINUATION/WITHDRAWAL OF SUBJECTS
All entry  criteria, including test results, need to be confirmed before the first dose.
7.1 Inclusion Criteria 
Subject eligibilit y is determined according to the following criteria before entry  into the study :
1.In the opinion o f the invest igator, the subject is capable of understanding and complying wit h 
protocol  requi rements.
2.The subject or, when applicable, the subject’s legally acceptable representative signs and dates 
a wri tten, informed consent form and any  required privacy  authori zation before the init iation 
of any study procedures including request ing that a subject fast for any laboratory evaluat ions. 
3.The subject is a healthy male or female not of childbearing potential adult who is aged 18 to 55 
years, inclusive, at the time of informed consent and first study  drug dose.
4.The subject weighs at least 45 kg and has a BMI f rom 18.0 to 30.0 kg/m 2, incl usive at 
Screening. 
5.A male subject who is nonsterilized* and sexually active wit h a female partner of childbearing 
potenti al* agrees to use adequate contraception* from signing of informed consent throughout 
the duration of the study  and for 90 days plus 5 half -lives (95 day s) after l ast study  drug dose. 
*Definit ions and acceptable methods of contraceptio n are defined in Appendix D.
6.A female subject with no childbearing potential, defined as a subject that has been surgically 
sterilized (hysterectomy , tubal  ligat ion, or bilateral oophorectomy) or who is postmenopausal 
(defined as continuous amenorrhea of at least 12 months and FSH >40 IU/L).
7.2 Exclusion Criteria
Any subject who meets any  of the fo llowing cri teria will not qualify  for entry  into the study :
1.The subject has received any invest igational co mpound within 4 weeks before Screening Visit. 
The 4 -week window will be derived fro m the date of the last trial procedure and/or AE related 
to the trial procedure in the previous trial to the Screening Visit of the current trial.
2.The subject is an immediate family member, study site emplo yee, or i s in a dependent 
relationship with a study  site em ployee who i s involved in the conduct of this study  
(eg,spouse, parent, child, sibling) or may consent under duress.
3.The subject has uncontrolled, clinically significant neuro logical (including seizure disorders), 
cardi ovascular, pulmo nary, hepat ic, renal, metabo lic, gastrointestinal, urologic, immuno logic, 
endocrine disease, or psy chiatri c disorder, or other abnormalit y, which m ay impact the abilit y 
of the subject to participate or potentially confound the study results. It is the responsibilit y of 
the inv estigator to assess the clinical significance; however, consultation wit h the Takeda 
Medical Moni tor m ay be warranted.
4.The subject has a known hypersensit ivity to any  component of the formulat ion of TAK -831.
TAK -831
TAK -831-1005 Page 29of 84
Protocol Incorporating Amendment No. 02 19 March 2018
CONFIDENTIAL5.The subject has a posit ive urine drug result for drugs of abuse (defined as any illicit drug use) at 
Screening or Check -in.
6.The subject has a history  of drug abuse (defined as any  illici t drug use) or a hi story  of alcohol  
abuse (defined as >3 drinks per day) wit hin 5 year before the Screening visit or i s unwilling to 
agree to abstain from alcoho l and drugs throughout the study . (1 drink=12 oz. beer=5 oz. 
wine=1.5 oz. liquor.)
7.The subject has taken any excluded medicat ion, supplements, or food products during the time 
periods listed in the Excluded Medica tions and Di etary  Products tabl e listed in Section 7.3.
8.If female, the subject is pregnant or lactating or intending to become pregnant before, during, 
or wi thin 35 days after parti cipat ing in this study; or intending to donate ova during such time 
period.
9.If male, the subject intends to donate sperm during the course of this study or for 90 days plus 
5 half -lives (95 days) after the last dose of study  medication.
10.The subject has evidence of current significant cardio vascular, central nervous system, hepat ic, 
hematopoiet ic disease, renal dysfunction, metabo lic or endocrine dysfunct ion, seri ous allergy , 
asthma, hypoxemia, hypertensio n, seizures, or allergic skin rash. There is any finding in the 
subject’s medical history , physical  examinat ion, or safet y laboratory  tests giving reasonable 
suspicio n of a disease that would contraindicate taking TAK -831, or a similar drug in the same 
class, or that might interfere with the conduct of the study . Thi s includes, but is not limited to, 
pepti c ulcer di sease, seizure disorders, and cardiac arrhy thmias.
11.The subject has a QT interval with Fridericia’s correction method (QTcF) >450 ms (male 
subjects) or >470 ms (female subjects) or PR outside the range of 120 to 220 ms, confirmed 
with 1 repeat testing, at the Screening Visit and Check -in. If repeat testing is required, QTcF 
and PR values should be based on the average of the assessments.
12.The subject has current or recent (within 6 mo nths) gastrointest inal disease that would be 
expected to i nfluence the absorption of drugs (ie, a history  of malabsorpti on, esophageal 
reflux, peptic ulcer disease, erosive esophagit is, frequent [more than once per week] 
occurrence of heartburn, or any  surgical intervent ion).
13.The subject has a history  of cancer, except basal cell carcinoma that has been in remissio n for 
at least 5 y ears before first dose of study  medicat ion.
14.The subject has a posit ive test result for HBsAg, ant i-HCV, or HIV antibody /antigen at 
Screening.
15.The subject has used nicotine -containing products (including but not limited to cigarettes, 
pipes, ci gars, chewing tobacco, nicotine patch or nicotine gum) within 28 days before 
Check -in. Cotinine test is posit ive at Screening or Check -in.
16. T he subject has poor peripheral venous access.
TAK -831
TAK -831-1005 Page 30of 84
Protocol Incorporating Amendment No. 02 19 March 2018
CONFIDENTIAL17.The subject has donated or lost 450 mL or more of his or her blood volume (including 
plasmapheresis), or had a transfusion of any blood product within 45 days before the first dose 
of study  medicat ion.
18.The subj ect has a Screening or Check- in abnormal (clinically significant) ECG. Entry o f any 
subject with an abnormal (not clinically significant) ECG must be approved, and documented 
by signature by  the principal invest igator or designee.
19.The subject has a supine blood pressure outside 90 to 140 mm Hg for systolic and 50 to 90 mm 
Hg for diastolic, confirmed on repeat testing within a maximum o f 30minutes, at the 
Screening Visit or Check -in.
20. The subject has a resting heart rate outside 40 to 100 beats per minute co nfirmed on repeat 
testing wit hin a maximum o f 30 minutes, at the Screening Visit or Check -in (heart rate fro m 
the ECG does not apply ).
21.The subject has abnormal Screening or Check -in laboratory  values, confirmed by repeat 
assessment), that suggest a clinica lly significant underlying disease or subject with the 
following lab abnormalit ies: ALT and/or AST >1.5×ULN.
22. The subject has a risk of suicide according to the Investigator’s clinical judgment (eg, per
C
-SSRS), or has s cored “y es” on i tem 4 or i tem 5 of the Suicidal Ideat ion sect ion of the 
C-SSRS, if this ideat ion occurred in the past 6 months, or “yes” on any item of the Suicidal 
Behavior section, except for the “Non- Suicidal  Self-Injuri ous Behavi or”, if  this behavi or 
occurred in the past 2 y ears.
23.The subj ect has received TAK -831 in a previous clinical study .
7.2.1 Additional Exclusion Criteria for Cohort(s) With CSF Collection
Any subject who meets any  of the fo llowing cri teria will not qualify  for entry  into the study : 
1.The subject has had CSF co llection perfor med wit hin 30 days before Check- in.
2.The subject has a known hypersensit ivity to the anesthetic or its derivat ives used during CSF 
collect ion, or any  medicat ion used to prepare the area of lumbar puncture, or any  
allergy -related indicat ions to medication us ed for dilati on during the ey e examinat ion.
3.The subject has significant vertebral deformit ies (scoliosis or ky phosis), whi ch, in the opinio n 
of the invest igator, may interfere with lumbar puncture procedure. 
4.The subject has a history  of clinically  signifi cant back pain and/or injury.
5.The subject has local infect ion at the puncture site.
6.The subject has thrombocy topeni a or other suspected bleeding tendencies noted before
procedure.
7.The subject has developed signs and symptoms of spinal radiculopathy, includ ing lower 
extremit y pain and paresthesias.
TAK -831
TAK -831-1005 Page 31of 84
Protocol Incorporating Amendment No. 02 19 March 2018
CONFIDENTIAL8.The subject has any  focal neurol ogical defici t that might suggest an increase in intracranial 
pressure.
9.The subject has any  abnorm al findings on ophthalmo logical  assessment/fundoscopy  
suggest ive of raised intracra nial pressure (ie, optic disc swelling/edema; (uncontrolled) 
hypertensive ret inopathy ).
10.Subject suffers regularly fro m mo derate to severe headaches requiring analgesics.
11.Subjects with lower spinal malformat ions (on physical examinat ion or lumbar spine 
radiography ), local spinal infecti on, or other abnormalit ies that would exclude lumbar 
puncture (LP).
7.3 Excluded Medications ,Supplements, Dietary Products
Use of the agents in Table 7.a(prescri ption or nonprescri ption) is prohibited fro m the time points 
specified unt il subject is discharged from the unit. 
Table 7.a Prohibi ted Medications, Supplements, and Dietary Products
28 Days Before Check -in 7 Days Before Check -in 72 Hours Before Check -in 
Prescription medications OTC medications including aspirin 
or aspirin containing products (a)Products containing caffeine or 
xanthine
Neutraceuticals (eg, St. John’s wort, 
ginseng, kava kava, ginkgo biloba, 
Chinese herbs, and melatonin)Vitamin supplements poppy seeds
Immunization/Vaccines (b) Foods or beverages containing 
grapefruit or grapefruit juice, star 
fruit or star fruit juice, Seville -type 
(sour) oranges and marmalade, apple, 
orange, or pineapple juices, 
vegetables from the mustard green 
family  (eg, kale, broccoli, watercress, 
collard greens, kohlrabi, Brussels 
sprouts, mustard), and charbroiled 
meats
Nicotine-containing products Alcohol containing products
Intake of known OTC 
inhibito rs/inducers of CYPs 3A4/5, 
2C9, 2C19, 2D6, 1A2, 2B6, 2E1, and 
2A6 (c) 
CYP=cytochrome P -450, OTC=over -the-counter. 
(a) Occasional use of paracetamol ( 1 g/day) or ot her medication as approved by Takeda on a case -by-case basis is 
allowed. Lidocaine and epinephrine or other local anesthetics are not excluded for subjects undergoing lumbar 
puncture. Ibuprofen or acetaminophen may be used for any spinal headaches that may occur as a result of lumbar 
puncture.
(b) Inclusive of but not limited to H1N1 and other flu vaccinations.
(c) Omeprazole, lansoprazole, cimetidine, ranitidine, and chlorpheniramine.
TAK -831
TAK -831-1005 Page 32of 84
Protocol Incorporating Amendment No. 02 19 March 2018
CONFIDENTIALSubjects m ust be instructed not to take any  medicati ons including over -the-counter products, 
without fi rst consul ting wi th the investi gator.
7.4 Diet, Fluid, Activity
7.4.1 Diet and Fluid
Subjects in each cohort will be confined during dosing and be kept in the study  unit for 24 hours 
after the l ast dose for non -CSF cohorts and 48 hours after catheter removal in CSF cohorts. 
The total confinement period in non -CSF cohorts will be 19 days (Day  -2 to Day  17), 20 day s in 
CSF cohorts where an indwelling temporary  catheter is being used on Day  1 and Day  16 
(confinement fro m Day -1 to Day 19) , and 21 days in CSF cohorts where CSF is co llected through 
a single predose lumbar puncture on Day  -1 and through an indwelling catheter on Day 16 
(confinement from Day -2 to Day  19). Foll ow-up assessments will occur on Day 30 (±2) for all 
cohorts . (See S ection 3.0). An except ion to these minimum confinement periods will be made if a 
determinat ion is made to evaluate QT/QTc intervals for addit ional single doses of T AK-831 in 
non-CSF cohorts based on the established tolerated dose range.
During the confinement period, subjects will be given a menu that will include 3 meals and an 
evening snack, each containing approximately 30% fat (relat ive to the total calories). The meals 
served on dosing and PK assessment days (Days 1 and 16) should be ident ical; no breakfast will be 
served; also on these days, record whether the meals were fully consumed (100%), or if not, record 
the percentage consumed (0, 25%, 50%, 75%). The study menu should be recorded and submitted 
to the study  file wit h a copy  provided to the sponsor before the start of the study  (for PK day s 
only). 
If a blood draw or any study procedure coincides wit h a meal, the blood draw will take precedence 
followed by the study  procedure and then the meal.
TAK -831 (as a tablet or suspension formulation) or placebo will be administered in the morning 
(QD on Day  1 and Day s 3 through 16 in Cohorts 1 and 2) after a fast of at least 10 hours; subjects 
will be instructed to fast for an addit ional 4 hours on Day s 1, 3, and 16 and 2 hours for all ot her 
dose administration days. For cohorts with T2 formulat ion tablets, dose administration will be 
followed by a 240 mL of water. For cohorts with suspensio n formulat ion, dose administration will 
be followed by  two ri nses o f 80 m L of water each (total vo lume of rinse water=160mL). All 
subjects may  then consume water ad libitum wit h the except ion of 1 hour before and 1 hour after 
drug administration. Subjects do not have to fast when no dosing is scheduled or for addit ional 
doses administered on the same day if TAK -831 is administered more than once per day . 
7.4.2 Activity
Subjects will remain upright (seated, standing, or ambulatory ) for 4 hours following the dose 
administration, except as necessitated by the occurrence of an AE or study  procedures (eg, 
obtaining 12-lead ECG).
TAK -831
TAK -831-1005 Page 33of 84
Protocol Incorporating Amendment No. 02 19 March 2018
CONFIDENTIALSubjects will refrain fro m strenuous and/or unaccustomed exercise throughout the entire course of 
the study , from Check- in through Study  Exit/Early Terminat ion.
7.5 Criteria for Discontinuation or Withdrawal of a Subject
The primary  reason for d iscont inuat ion or wi thdrawal  of the subject from  the study  or study 
medicat ion shoul d be recorded in the electronic case report form (eCRF) using the fo llowing 
categori es.
1.AE. The subject has experienced an AE that requires early terminat ion because contin ued 
participat ion imposes an unacceptable risk to the subject’s health or the subject is unwilling to 
continue because of the AE.
a.Liver Funct ion Test (LFT) Abnormalit ies
Study  medicati on shoul d be discont inued immediately with appropriate clinical fo llow-up 
(including repeat laboratory  tests, until a subject’s laboratory  profile has returned to 
norm al/baseline status, see Section 10.2.8.5 ), if the fo llowing circumstances occur at any  
time during study  medicati on treatm ent:
–ALT or AST >8×ULN, or
–ALT or AST >5×ULN and persists for more than 2 weeks, or
–ALT or AST >3×ULN in conjunct ion with elevated total bilirubin >2×ULN or INR 
>1.5, or
–ALT or AST >3×ULN with a ppearance of fat igue, nausea, vomit ing, ri ght upper 
quadrant pain or tenderness, fever, rash and/or eosinophilia (>5%).
b.Subject discont inuat ion should be considered if there is a marked prolongat ion of the QTcF 
interval  during treatment with the study drug , especially if the measurements are confirmed 
from 
more than 1 ECG. The thresho lds for marked corrected QT (QTc) interval increases 
are considered to be >500 ms on any given QTcF measurement or >60 ms over baseline 
QTc and should be discussed wit h Takeda.
2.Significant protocol deviat ion. The discovery postrando mizat ion that the subject failed to meet  
protocol  entry  criteria or di d not adhere to protocol requirements, and continued participation 
poses an unacceptable risk to the subject’s health.
3.Lost to fol low-up. The subject did not return to the clinic and attempts to contact the subject 
were unsuccessful. Attempts to contact the subject must be documented.
4.Voluntary  withdrawal. The subject (or subject’s legally  acceptable representative) wishes to 
withdraw from the study . The reason for withdrawal, if provided, should be recorded in the 
eCRF.
Note: All attempts should be made to determine the underlying reason for the withdrawal and, 
where possible, the primary  underlying reason should be recorded (ie, wit hdrawal because of 
an AE).
TAK -831
TAK -831-1005 Page 34of 84
Protocol Incorporating Amendment No. 02 19 March 2018
CONFIDENTIAL5.Study  terminat ion. The sponsor, IRB, IEC, or regulatory  agency  terminates the study .
6.Other.
Note: The specific reasons should be recorded in the “specify” field of the eCRF.
7.6 Procedures for Discontinuation or Withdrawal of a Subject
The invest igator may discont inue a subject’s study participat ion at any t ime during the study when 
the subject m eets the study  terminat ion criteria described in Sect ion 6.5.5 . In addit ion, a subject 
may discont inue his or her participat ion without giving a reason at any  time during the study . 
Shoul d a subject’s participat ion be discont inued, the primary criterion for terminat ion must be 
recorded by  the invest igator. In addition, efforts should be made to perform all procedures 
scheduled for the Early Terminat ion Visit. Discont inued or withdrawn subjects may be replaced to 
ensure that a minimum o f 6 subjects are completed for each cohort. This will be examined by the 
team  on a case -by-case basis.
7.7 Subject Replacement
Subjects m ay be repl aced on a case -
by-case basis at the discret ion of the sponsor.
TAK -831
TAK -831-1005 Page 35of 84
Protocol Incorporating Amendment No. 02 19 March 2018
CONFIDENTIAL8.0 CLINICAL STUDY MATER IAL MANAGEMENT
8.1 Clinical Study Drug
Details regarding the active drug and placebo in tablet dosag e form  and the extem poraneous 
preparati on can be found in the IB and compounding manual respect ively. Clinical study drug will 
be packaged to support enrollment and replacement subjects as required. When a replacement 
subject is required, the sponsor needs to be contacted prior to dosing .
8.1.1 Clinical Study Drug Labeling
Clinical study  drug will  be affixed wit h a clinical label in accordance with regulatory 
requi rements.
8.1.2 Clinical Study Drug Inventory and Storage
Clinical study drug must be stored in a secure, l imited-access location and remained in the origina l 
container unt il dispensed. The storage condit ion and temperature excursion informat ion can be 
found in the compounding manual. Receipt and dispensing of study  drug m ust be recorded by  
authori zed personnel at the tri al site.
8.1.3 Clinical Study Drug Blinding
This is an invest igator and subject blinded, sponsor -open study . The invest igator and subjects are 
blinded to treatment assignment. The unblinded study  drug supply  will be provi ded to an 
unblinded pharmacist or other qualified trial site personnel who will blind the trial supplies.
Treatment ident ity (name and strength or potency ) will be incl uded on the study  drug container 
label; rando mization code/disclosure envelopes or lists will be provided as per site procedure .
8.1.4 Randomization Code Creation and Storage
Randomization personnel o f the sponsor or designee will generate the randomization schedule. All 
rando mizat ion informat ion will  be stored in a secured area, accessible only  by authori zed 
personnel.
8.1.5 Clinic al Trial Blind Maintenance/Unblinding Procedure
The invest igational drug blind is maintained through a rando mizat ion schedule held by the 
rando mizat ion personnel.
The invest igational drug blind shall not be broken by the investigator unless informat ion 
concerning the investigational drug is necessary  for the m edical treatment of the subject. The 
investigator should perform all study  assessments and causalit y evaluat ion, if possible, before 
unblinding. In the event of a medical emergency, if possible, the me dical  monitor or desi gnee 
shoul d be contacted before the invest igational drug blind is broken to discuss the need for 
unblinding. The sponsor must be notified as soon as possible if the invest igational drug blind is 
broken .
TAK -831
TAK -831-1005 Page 36of 84
Protocol Incorporating Amendment No. 02 19 March 2018
CONFIDENTIALIndividual code break envelopes will be provided for all subjects to the invest igator or designee by 
the sponsor or designee. Each sealed envelope containing the rando mizat ion code and treatment 
will be kept in a medicat ion storage room, which is locked with restricted access. If opened, the 
name of the person who opened it, the date and time of opening and the reason for opening must be 
written on the envelope. A similar mechanism may be subst ituted for envelopes (eg, scratch -off 
cards).
8.1.6 Accountability and Destruction of Sponsor- Supplied Drugs
The invest igator is responsible for keeping accurate records of the clinical study drug received 
from the sponsor or designee, the amount dispensed to and returned by the subjects and the amount 
remaining at the conclusio n of the study. For the stud y site, the sponsor personnel or designee will 
provi de appropri ate documentati on that m ust be completed for clinical study  drug accountabilit y, 
return, and destruction .
TAK -831
TAK -831-1005 Page 37of 84
Protocol Incorporating Amendment No. 02 19 March 2018
CONFIDENTIAL9.0 STUDY PROCEDURES
The fo llowing sect ions describe the study  procedures and data to be co llected as indicated in the 
Schedule of Study Procedures (Section 3.0). For each procedure, subjects are to be assessed by the 
same investigator or site personnel whenever possible. Please note that it may beco me necessary to 
perform  the f ollowing procedures at unscheduled time periods, per the discret ion of the 
investigator.
9.1 Administrative Procedures
9.1.1 Informed Consent Procedure
Inform ed consent m ust be obtained before the subject entering into the study  and before any  
protocol -directed procedures are performed, including requesting that a subject fast for laboratory 
evaluat ions. PGx informed consent is a co mponent of the overall study  informed consent . The 
requi rements of informed consent are described in Section 13.2.
When subjects have performed screening assessments before study , the data from Screening using 
a generic screening consent form can be used in this study  for those who were subsequent ly 
enrolled, as long as the procedure was performed within the protocol screening to enrollment 
window.
The sampling of who le blood for PGx analys is is mandatory; every  subject m ust si gn informed 
consent to participate in the study. A separate optional informed consent may be required for PGx.
9.1.1.1 Assignment of Screening and Randomization Numbers
All consented subjects will be given a unique screening n umber that will be used to identify the 
subject for all procedures that occur before randomizat ion or allocat ion. Each subject will be 
assigned only  1 screening number. Screening numbers must not be re -used for different subjects. 
Any subject who is screen ed m ultiple times will be assigned a new screening number for each 
screening event.
Subjects who qualify for the study  will be assigned a 4 -digit rando mizat ion sequence number 
starting with X001 in the order in which they are enrolled into their respective Cohort X, and ended 
with X008. For example, for Cohort 2, the randomizat ion numbers will be 2001 to 2008. The 
number will be assigned by the clinic site personnel in sequent ial order beginning and ending wit h 
the numbers specified for each cohort. The 4 -dig
it randomizat ion number will dictate which 
treatm ent will be assigned to each subject based on the randomizat ion schedules distributed only to 
the authorized personnel (eg, pharmacist). Once a rando mizat ion number is assigned to a subject, it 
can never be reassigned to another subject. A single subject cannot be assigned more than 1 
rando mizat ion number.
For a subject's replacement, the rando mizat ion number will be X9XX, where X's are the same as 
those for the original subject. For example, the replacemen t number for Subject 3005 will be 3905. 
The repl acement will be given the same drug as that for the original subject.
TAK -831
TAK -831-1005 Page 38of 84
Protocol Incorporating Amendment No. 02 19 March 2018
CONFIDENTIAL9.1.1.2 Study Drug Assignment
On Day  1, subjects will  be assigned a randomizat ion number in ascending numerical order at the 
study  site. The rando mizat ion number encodes the subject assignment to either the TAK -831 or the 
placebo arm  of the study , according to the randomization schedule generated before the study  by 
the sponsor’s Statist ics Depart ment or designee. Each participant will be dispensed blinded study  
treatm ent, l abeled wi th his/her unique rando mizat ion number, throughout the study. If a subject is 
discontinued before the first dose on Day  1, the repl acement subject will have the same 
rando mizat ion number as the discontinued subject.
9.1.2 Inclu sion and Exclusion
Each subject is assessed through randomizat ion, according to the eligibilit y criteria provi ded in 
Secti on 7.0.
9.1.3 Medical History/ Demography
Qualifie d site personnel  are to collect subject significant medical history  and concurrent medical 
condi tion per the si te’s standard of care and appropriate clinical judgment as well as subject 
demographics.
9.1.4 Medication History/Concomitant Medications
Medicat ions are defined as prescription and over- the-counter drugs, vitamin supplements, 
nutraceuticals, and oral herbal preparat ions. Qualified site personnel are to review subject 
medicat ion use.
9.2 Clinical Procedures and Assessments
9.2.1 Full Physical Examination
Qualified site personnel  will conduct full  physical  examinat ions.
A co mprehensive clinical neurological assessment (with a focus on cerebellar signs), will be 
perform ed on all subjects (except on CSF collect ion days in CSF cohorts) as indicated in the 
Secti on 3.0Schedule of Study  Procedures.
The neuro logical examinat ion will include: 1. Mental status, 2. Cranial nerves I –XII; 3. Motor 
(muscle bulk; tone; po wer; reflexes); 4. Sensory  (pain; tem perature, light touch and 
propri ocepti on); 5. Cerebellar funct ion: a) Gai t; b) Walk heel -toe in a straight line; c) Romberg’s 
test; d) In tention trem or; e) Assess tone at shoulder, elbow and wrist; f) Test for 
dysdiadoc hokinesis by rapid alternat ing mo vements of hands; g) Test for dysmetria by finger -nose 
test and heel- shin test; h) Assess eye mo vements for nystagmus; i) Assess speech for staccato 
cerebellar speech; j) Assess for titubat ion.
For the ey e examinat ion: a ba seline (Day  
-2 for singl e lumbar puncture, Day  -1 for indwelling 
catheter, and Day  15) ophthalm ological  assessment of the retina (fundoscopy ), as well as a repeat 
assessment before performing the lumbar puncture for CSF collect ion
.
TAK -831
TAK -831-1005 Page 39of 84
Protocol Incorporating Amendment No. 02 19 March 2018
CONFIDENTIALAny abnormal finding on a pretreatment physical examinat ion assessment must be assessed as Not 
Clinically Significant (NCS) or Clinically Significant (CS) by the invest igator and recorded in the 
source document and eCRF. All CS findings/changes will be recorded as a pretreatment event or 
concurrent medical condit ion in the source document and on the appropriate eCRF described in 
Secti on 10.0.
On subsequent examinat ions, any  abnorm al change from  the pretreatm ent phy sical examinat ion 
assessment occurring immediately  before the first dose of the invest igational drug on Day  1 in 
each cohort must be assessed as NCS or CS by  the investi gator and reco rded i n the source 
docum ent and eCRF. Any CS change or new diagnosis as a result of a CS change, as determined 
by the investigator, will be recorded as an AE in source documentation and on the AE eCRF 
described in Section 10.0.
9.2.2 Height and Weight
Body  weight and height will be obtained with the subject’s shoes off, and jacket or coat removed.
9.2.3 BMI
BMI equals a person's weight in kilograms divided by height in meters sq uared (BMI=kg/m2). 
Body  weight and height will be obtained with the subject’s shoes off and jacket or coat removed.
BMI will be rounded to the nearest whole number according to the standard convent ion of 
0.1to0.4 round down and 0.5 to 0.9 round up.
9.2.4 Vital Signs
Body  temperature will be measured with an oral (temperature taken at floor of the mouth) or 
tympanic thermo meter. The same method (eg, oral or tympanic) must be used for all subsequent 
measurements for each individual subject and should be the same for all subjects.
Subjects should rest in a supine posit ion for at least 5 minutes before having vital sign 
measurements obtained. Vital signs will include heart rate, respirat ion rate, and systolic and 
diastolic blood pressure. The same method (eg, same s ize cuff, manual or automated) must be used 
for all measurements for each individual subject and should be the same for all subjects.
9.2.5 ECGs
Speci al care must be taken for proper lead placement by qualified personnel. Skin should be clean 
and dry  before lead placement. Subj ects m ay need to be shaved to ensure proper lead placement. 
Female subjects may need to remove their bra.
Subjects should be resting in a supine posit ion for at least 5 minutes before each ECG 
measurement.
QTcF will be used to calculate QT intervals in this study .
TAK-831
TAK-831-1005 Page 40 of 84
Protocol Incorporating Amendment No. 02 19 March 2018
CONFIDENTIAL9.2.5.1 Safety ECG
Standard 12-lead ECG (singlet) will be recorded. When an ECG is scheduled at the same time as 
blood draws, or vital signs then the ECG will take priority followed by vital signs and then the 
blood draw. Vitals will be collected within a pproximately 0.5 hour before the scheduled timepoint. 
The blood draw will be then performed as closely as possible to the ECG. If an ECG coincides 
with a meal or CSF collection, ECG will take preced ence followed by CSF co llection and then the 
meal.
All stationary 12-lead EC G machines will be supplied by the site. Subjects should be resting in a 
supine position for at least 5 minutes prior to each ECG measurement. Should technical difficulties 
occur during recording of the ECG, a reasonable a ttempt should be made to rep eat the ECG shortly 
after the failed attempt.
Before each Treatment Period/cohort, a predose ECG will be obtained within approximately 
1 hour before dosing TAK- 831. This measurement will be used as the baseline. The principal 
investigator should arrange to have a study ca rdiologist available as needed to review ECG 
tracings with abnormalities.
If a subject demonstrates an increase in QTcF interval ≥40 msec compared with a predose baseline 
measurement, the ECG w ill be repeated within 30 minutes. The average value of the QTcF interval 
from the 2 ECGs will represent the value at that time point. If the average QTcF interval increase 
from Baseline for any postdose time point is ≥40 msec, the subject will continue to be monitored 
by repeat 12-lead ECGs every 60 minutes for at least 4 hours or until the QTcF is within 40 msec of 
the baseline value. If prolongation of the QTcF interval ≥40 msec persists, a consultation with a 
study cardiologist may be appropriate and the sponsor should be notified.
If the QTcF interval is #500 msec on repeat measurements, the sponsor should be notified and the 
ECGs should be reviewed by a cardiologist. The subject should be monitored (until the QTcF is 
<500 msec) or should be considered for transfer to a location where closer monitoring is available.
If the subject has unstable hemodynamics, or has any clinically significant dysrhythmias noted, the 
subject should be immediately transferred to an acute care setting for definitive therapy. 
If repeat ECGs are required, the clinical site will decide whether to leave the electrodes in place or 
mark the position of the electrodes for subsequent ECGs. To mark the position of the electrodes, 
12-lead electrode sites will be marked on the skin of each subject with an ECG skin marker pen to 
ensure reproducible electrode placement.
The following ECG parameters will be recorde d: heart rate, PR-interval, QRS-duration, 
QT-interval, QTcF interval, and the interpretation of the ECG profile by the principal investigator.
9.2.5.2CCI
CCI
TAK-831
TAK-831-1005 Page 41 of 84
Protocol Incorporating Amendment No. 02 19 March 2018
CONFIDENTIAL9.2.6 C-SSRS
Suicidality will be assessed by the use of the C-SSRS [10,11] . The C-SSRS was developed by 
researchers at Columbia University as a tool to help systematically assess suicidal ideation and 
behavior in subjects during participation in a clin ical trial of centrally-acting drugs. The C-SSRS is 
composed of 3 questions addressing suicidal behavior and 5 questions addressing suicidal 
ideation, with subquestions assessing the severi ty. The Screening/Bas eline C-SSRS (Lifetime) 
will be administered at Screening for all subjects , by the principal investigator or a trained 
designee.
9.2.7 Study Drug Administration
This is an investigator and subject blinded study; therefore, TAK-831 or matching placebo will be 
administered orally on Day 1 and Days 3 through 16 in a blinded fashion.
9.2.7.1 Monitoring Subject Treatment Compliance
Study medication will be administered while subjects are under observation in the clinical research 
unit. Following administration of the study medication, appropriate mouth and/or hand checks will 
be performed to ensure that the dose is swallowed and noted in the source document . The date and 
time of each dose will be recorded in the source documents and on the eCRFs. An inventory of the 
study medication supplies dispensed will be pe rformed by the site pharmacist or authorized study 
designee and recorded onto the Drug Accountability Log in the subject’s source document records 
or equivalent. The exact dose time of consecutive subjects may be staggered to facilitate logistics 
at the site.CCI
TAK -831
TAK -831-1005 Page 42of 84
Protocol Incorporating Amendment No. 02 19 March 2018
CONFIDENTIAL9.2.8 AE Monitoring
AE m onitoring begins foll owing signing of informed consent. Changes in subject healt h status 
from baseline assessment to trial drug administration should be captured in the subject’s medical 
history . A com plete descri ption of  AE collect ions and procedures is provided in Sect ion 10.0.
9.2.9 Laboratory Procedures and Assessments
Laboratory  samples will be collected in accordance with acceptable laboratory  procedures. 
Samples will  be taken on the day s stipulated in the Schedule of Study Procedures (Section 3.0).
9.2.9.1 Clinical Laboratory Tests
Hematology
Hem atology will consist of the following tests:
Erythrocy tes (red blood cells) Hemoglobin
Hematocrit Platelets
Leukocytes (white blood cells) with absolute differential Coagulation panel (PT/INR, aPTT) for CSF cohort 
subjects
Urinalysis
Urinalysis will consist of the fo llowing tests:
Protein Glucose
Blood Nitrite
Urine microscopy  will be perform ed if urinalysis is abnormal. Microscopy  consists of red blood 
cell/high -power field, white blood cell/high- power field, and casts.
Chemistry 
Chemistry  evaluat ions will consist of the fo llowing standard chemistry  panel:
Albumin Alkaline phosphatase
ALT AST
Blood urea nitrogen Calcium
Carbon dioxide Chloride
Creatinine Glucose
Gamma -glutamyl transferase Sodium
Potassium Bilirubin (total), if above ULN total bilirubin will be 
fractionated
Protein (total)
TAK-831
TAK-831-1005 Page 43 of 84
Protocol Incorporating Amendment No. 02 19 March 2018
CONFIDENTIAL9.2.9.2 Diagnostic Screening
Serum/Blood
Serum diagnostic evaluations will include the following tests:
Alcohol Hepatitis Screen (HBsAg, HCV antibody)
hCG (female subjects only) HIV
FSH (female subjects only)
Urine
A urine drug screen will include the following tests: 
Amphetamines Cotinine
Barbiturates 3,4-methylenediox y-methamphetamine (MDMA)
Benzodiazepines Methadone/Metabolite
Buprenorphine/Metabolite Opiates
Cannabinoids Oxycodone/Oxymorphone
Cocaine/Metabolites. P hencyclidine
9.3 PK, PD, and PGx, Samples
Primary specimen collection par ameters are provided in  Table 9.a.
Table 9.a Primary Specimen Collections
Specimen NamePrimary 
SpecimenPrimary 
Specimen 
Derivative Description of Intended UseSample 
Collection
(a) Only in selected cohort(s).CCICCI
TAK-831
TAK-831-1005 Page 44 of 84
Protocol Incorporating Amendment No. 02 19 March 2018
CONFIDENTIAL9.3.1 PK Measurements 
The PK parameters of TAK-831 will be derived using noncompartmental analysis methods and 
will be determined from the concentration-time data for all evaluable subjects. Actual sampling 
times, rather than scheduled sampling times, will be used in all PK computations involving 
sampling times for plasma PK parameters. 
9.3.1.1 PK Sample Collection
PK blood and CSF samples for TAK-831 concentrations will be collected as specified in the 
Schedule of Trial Procedures (See Section  3.0).
The actual date and time of each PK (blood and CSF) sample collection as well as the date and 
time of study drug dosing for the most recent dose will be recorded accurately in the eCRF.
Instructions for sample processing and shipment are provided in the laboratory manual.
9.3.1.2 PK Sample Analysis
Plasma and CSF concentrations of TAK-831 will be  measured by a validated HPLC with tandem 
mass spectrometry assay.
Part of the archival plasma and CSF samples will be used for potential analysis of unknown 
metabolite ch aracterization, if appropriate.
9.3.2 PD Measurements
9.3.2.1 PD Sample Collection
Blood
The actual time of sample co llection, time since last dose was administered, and time since last 
meal will be recorded on the source document and eCRF.CCICCI
TAK-831
TAK-831-1005 Page 45 of 84
Protocol Incorporating Amendment No. 02 19 March 2018
CONFIDENTIALInstructions for sample processing and shipment are provided in the laboratory manual.
CSF
9.3.2.2 PD Sample Analysis
9.3.3 PGx Measurements 
The sampling of whole blood for PGx and genotypi ng analysis is mandatory; every subject must 
sign informed consent in order to participate in this study. DNA samples will be used to evaluate 
drug metabolic enzyme and transporter polymorphisms. Also, since PGx is an evolving science, 
many genes and their functions are not yet fully understood. Future data may suggest a role of 
some of this gene in drug response, which may lead to additional hypothesis-generating 
exploratory research and diagnostic development on stored samples.
The samples will be stored for no longer than 15 years after completion of the TAK-831 study 
and/or until the drug development of TAK- 831 is no longer actively pursued by Takeda or its 
collaborators. No samples will be stored for longer than permitted by the applicable law and 
samples will be destroyed upon notification from Takeda. “Stored samples” are defined as samples 
that are double coded (the samples are stripped of all personal identifying information but a key 
links the samples to the clinical data collected from the sample donor) and are used in the analysis 
of investigational drug or related drug.
9.3.4 Total Blood  Volume
Approximately 380 mL of total blood volume will be collected.
9.3.5 Confinement
Subjects in each cohort will be confined during dosing and be kept in the study unit for 24 hours 
after the last dose for non-CSF cohorts and 48 hours after catheter removal in CSF cohorts. 
The total confinement period in non-CSF cohorts will be 19 days (Day -2 to Day 17), 20 days in 
CSF cohorts where an indwelling temporary catheter is being used on Day 1 and Day 16 CCICCI
TAK -831
TAK -831-1005 Page 46of 84
Protocol Incorporating Amendment No. 02 19 March 2018
CONFIDENTIAL(confinement fro m Day -1 to Day 19); and 21 days in CSF cohorts where CSF is collected through 
a single predose lumbar puncture on Day  -1 and through an indwelling catheter on Day 16 
(confinement from Day -2 to Day  19). Foll ow-up assessments will occur on Day 30 (±2) for all 
cohorts . An except ion to these minimum confinement periods will be made if a determinat ion is 
made to evaluate QT/QTc intervals for additional single doses of TAK -831 in non -CSF cohorts 
based on the established tolerated dose range.
TAK -831
TAK -831-1005 Page 47of 84
Protocol Incorporating Amendment No. 02 19 March 2018
CONFIDENTIAL10.0 ADVERSE EVENTS
10.1 Definitions and Elements of AEs
An AE is defined as any un toward m edical occurrence in a clinical invest igation subject who has 
signed inform ed consent to participate in a study; it does not necessarily  have to have a causal 
relationship with the treatment.
An AE can therefore be any unfavorable and unintended si gn (eg, a clinically significant abnormal 
laboratory  finding), symptom, or disease temporally  associ ated wi th the use of a drug, whether or 
not it is considered related to the drug.
An untoward finding generally may:
Indicate a new diagnosis or unexpected worsening of a preexist ing condit ion. (Intermittent 
events for pre -exist ing condit ions or underlying disease should not be considered AEs.)
Necessitate therapeutic intervent ion.
Requi re an invasive diagnostic procedure.
Requi re discontinuation or a change in dose of study medicat ion or a concomitant medicat ion.
Be considered unfavorable by the invest igator for any reason.
Diagnoses versus signs and symptoms:
Each event should be recorded to represent a single  diagnosis. Acco mpanying signs (including 
abnorm al laboratory  values or ECG findings) or symptoms should NOT be recorded as 
additional AEs. If  a diagnosis is unknown, sign(s) or symptom(s) should be recorded 
appropriately  as an AE(s).
Laboratory  values and ECG findings:
Changes in laboratory  values or EC G parameters maybe considered AEs if they are judged to 
be clinically  significant (i e, if som e act ion or intervent ion is required or if the investigator 
judges the change to be beyo nd the range of normal physio logic fluctuati on). A l aboratory  
re-test and/o r continued monitoring of an abnormal value are not considered an intervention. In 
addition, repeated or addit ional noninvasive testing for verificat ion, evaluat ion or m onitoring 
of an abnorm ality is not considered an intervention.
If abnormal laboratory v alues or ECG findings are the result of pathology for which there is an 
overall diagnosis (eg, increased creat inine in renal failure), the diagnosis only should be 
reported appropriately  as an AE.
Pre-exist ing condit ions:
A pre -exist ing condit ion (present at the time of signing of informed consent) is considered a 
concurrent medical history  condi tion and shoul d NOT be recorded as an AE. A baseline 
evaluat ion (eg, laboratory test, ECG, x -ray) should NOT be recorded as an AE unless related to 
a study  procedur e. However, if the subject experiences a worsening or complicat ion of such a 
TAK -831
TAK -831-1005 Page 48of 84
Protocol Incorporating Amendment No. 02 19 March 2018
CONFIDENTIALconcurrent medical history  condi tion, the worsening or complicat ion should be recorded 
appropriately  as an AE (worsening or complicat ion occurs after informed consent is signed). 
Invest igators should ensure that the event term recorded captures the change in the condit ion 
(eg, “worsening of…”).
If a subject has a pre -exist ing episodic condit ion (eg, asthma, epilepsy), any occurrence of an 
episode should only be captured as an AE if the episodes beco me more frequent, serious, or 
severe in nature, that is, invest igators should ensure that the AE term recorded captures the 
change from Baseline in the condit ion (eg “worsening of…”).
If a subject has a degenerat ive concurrent condition ( eg, cataracts, rheumatoid arthritis), 
worsening of the condit ion should only be captured as an AE if occurring to a greater extent to 
that which would be expected. Again, investigators should ensure that the AE term recorded 
captures the change in the cond ition (eg, “worsening of…”).
Worsening of AEs:
If the subject experiences a worsening or complicatio n of an AE aft er the first administration of 
study  medicat ion or after any  change in study  medicat ion, the worsening or complicat ion 
should be recorded as a new AE. Invest igators should ensure that the AE term recorded 
captures the change in the condit ion (eg, “worsening of…”).
Changes in severit y of AEs:
If the subject experiences a change in the severit y of an AE that is not associated with a change 
in study medication, the event shoul d be captured once with the maximum severit y recorded.
Prepl anned surgeries or procedures:
Prepl anned procedures (surgeries or therapies) that were scheduled before signing of informed 
consent are not considered AEs. However, i f a preplanned procedure is performed early (eg, as 
an emergency) because of a worsening of the pre- exist ing condit ion, the worsening of the 
condi tion shoul d be captured appropriately  as an AE. Com plicat ions result ing from any 
planned surgery  should be reported as AEs.
Elect ive surgeries or procedures:
Elect ive procedures performed where there is no change in the subject’s medical condit ion 
shoul d not be recorded as AEs but should be documented in the subject’s source documents. 
Com plicat ions result ing froman elect ive surgery should be reported as AEs.
Overdose:
An overdose is defined as a known deliberate or accidental administration of investigational 
drug, to or by  a study  subject, at a dose above that which is assigned to that individual subject 
according to the study protocol. It is up to the investigator or the reporting physician to decide 
whether a dose is to be considered an overdose, in consultation wit h the sponsor.
All cases of overdose (with or without associated AEs) will be documented o n an Overdose 
page of the eCRF, in order to capture this important safet y information consistent ly in the 
TAK -831
TAK -831-1005 Page 49of 84
Protocol Incorporating Amendment No. 02 19 March 2018
CONFIDENTIALdatabase. AEs associated with an overdose will be documented on AE CRF(s) according to 
Secti on 10.2.8 .
SAEs of overdose should be reported according to the procedure outlined in Sect ion 10.2.8 .
In the event of drug overd ose, the subject should be treated symptomat ically.
10.1.1 SAEs
An SAE is defined as any untoward medical occurrence that at any  dose:
1.Results in DEATH.
2.Is LIFE THREATENING.
The term “life threatening” refers to an event in which the subject was at risk of death at the 
time of the event; it does not refer to an event that hypothetically might have caused death 
if it were m ore severe.
3.Requi res inpat ient HOSPITALIZATION or prolongation of exist ing hospitalizat ion.
4.Results in persistent or significant DISABILITY/INCA PACITY.
5.Is a CONGENITAL ANOMALY/BIRTH DEFECT.
6.Is an IMPORTANT MEDICAL EVENT that satisfies any of the fo llowing:
May require intervent ion to prevent items 1 through 5 above.
May expose the subject to danger, even though the event is not immediately life 
threatening or fatal or does not result in hospitalization.
Includes any event or synonym described in the Takeda Medically  Significant AE List 
(Table 10.a).
Table 10.a Takeda Medically Significant AE List 
Term
Acute respiratory failure/acute respiratory 
distress syndromeHepatic necrosis
Acute liver failure
Torsade de pointes/ventricular fibrillation/
ventricular tachycardiaAnaphy lactic shock
Acute renal failure
Malignant hypertension Pulmonary hypertension
Convulsive seizures Pulmonary fibrosis
Agranulocytosis Confirmed or suspected endotoxin shock
Aplastic anemia Confirmed or suspected transmission of infectious agent by 
a medicinal productToxic epidermal necrolysis/
Stevens -Johnson syndromeNeuroleptic malignant syndrome/malignant hyperthermia
Spontaneous abortion/stillbirth and fetal death
TAK -831
TAK -831-1005 Page 50of 84
Protocol Incorporating Amendment No. 02 19 March 2018
CONFIDENTIALAEs that fulfill 1 or more of the serious criteria above are to be considered SAEs and should be 
reported and fo llowed up in the same manner (see Sections 10.1 and 10.1.1 ).
10.1.2 Special Interest AEs
No AEs of special interest have been ident ified for TAK -831.
10.2 AE Procedures
10.2.1 Assigning Severity/Intensity of AEs
The different categories o f severit y/intensity are:
Mild: An AE that is usually transient and may require only minimal treatment or 
therapeuti c intervent ion. The event does not generally  interfere wi th usual 
activit ies o f daily li ving.
Moderate: An AE that is usually alleviated with addit ional specific therapeutic 
intervent ion. The event interferes wit h usual activit ies of daily living, causing 
discomfort but poses no significant or permanent risk of harm to the research 
participant.
Severe: An AE that interrupts usual activit ies of daily living, or significant ly affects 
clinical status, or may  require intensive therapeutic intervent ion.
10.2.2 Assigning Causality of AEs
The rel ationship of each AE to study  medicati on(s) will be assesse d using the fo llowing 
categori es:
Related: An AE that fo llows a reasonable temporal sequence fro m administration of a 
drug (including the course after withdrawal o f the drug), or for whi ch a causal  
relationship is at least a reasonable possibilit y, that is , the relat ionship cannot be 
ruled out , although factors other than the drug, such as underlying diseases, 
complicat ions, conco mitant drugs and concurrent treatments, may also be 
responsible.
Not Rel ated: An AE that does not follow a reasonable temporal sequence fro m ad ministration 
of a drug and/or that can reasonably be explained by  other factors, such as 
underlying diseases, complicat ions, conco mitant medi cations and concurrent 
treatm ents.
10.2.3 Start Date 
The start date of the AE is the date that the first signs/symptom s were noted by  the subject and/or 
investigator.
TAK -831
TAK -831-1005 Page 51of 84
Protocol Incorporating Amendment No. 02 19 March 2018
CONFIDENTIAL10.2.4 End Date 
The end date of the AE is the date at which the subject recovered, the event resolved but with 
sequelae or the subject died.
10.2.5 Pattern of AE (Frequency) 
Episodi c AEs (eg, headache) or those which occur repeatedly over a period of consecutive days are 
intermittent. All other events are continuous.
10.2.6 Action Taken With Study Treatment
Drug withdrawn: a study  medicat ion is stopped because of the particular AE.
Dose not changed: the particular AE di d not requi re stopping a study  medicat ion.
Unknown: only to be used if it has not been possible to determine what action has been taken.
Not applicable: a study  medicat ion was stopped for a reason other than the particular AE, for 
example, the study has been terminated, the subject died, dosing with study medication had not
yet started or dosing with study  medicat ion was already  stopped before the onset of the AE.
Dose reduced: the dose was reduced because of the particular AE.
Dose increased: the dose was increased because of the particular AE.
Drug interrupted: the dose was interrupted due to the particular AE.
10.2.7 Outcome 
Recovered/reso lved: subject returned to first assessment status with respect to the AE.
Recovering/resolving: the intensit y is lowered by one or m ore stages: the diagnosis has or 
signs/symptom s have alm ost disappeared; the abnormal laboratory  value improved, but has 
not returned to the normal range or to the baseline value; the subject died fro m a cause other 
than the particular AE with the condi tion rem aining “recovering/resolving.”
Not recovered/not resolved: there is no change in the diagnosis, signs or symptoms; the 
intensity of the di agnosis, signs/symptoms or laboratory  value on the l ast day  of the observed 
study peri od has beco me worse than when it started; is an irreversible congenital ano maly; the 
subject died fro m another cause with the particular AE state remaining “not recovered/not 
resolved.”
Recovered/reso lved with sequelae: the subject recovered fro m an acute AE but was left with 
perm anent/si gnificant impairment (eg, recovered from a cardiovascular accident but with 
some persisting paresis).
Fatal : an AE that i s considered as the cause of death.
Unknown: the course of the AE cannot be fo llowed up because o f hospital change or residence 
change at the end of the subject’s participation in the study .
TAK -831
TAK -831-1005 Page 52of 84
Protocol Incorporating Amendment No. 02 19 March 2018
CONFIDENTIAL10.2.8 Collection and Reporting of AEs, SAEs, Special Interest AEs, and Abnormal LFTs
10.2.8.1 Collection Period
Collect ion of AEs (ie, AEs, SAEs, Special Interest AEs, and Abnormal LFTs) wi ll commence at 
the time the subject signs the informed consent. Routine co llection of AEs will cont inue until the 
follow-up phone call on Day  30 (±2 days), approximately 15 days after the last dose of 
investigat ional product. For subjects who discont inue b efore the administration of study  
medicat ion, AEs will be fo llowed unt il the subject discontinues study  parti cipat ion. 
10.2.8.2 Reporting AEs
At each study  visit, the investi gator will assess whether any  subjective AEs have occurred. A 
neutral  quest ion, such as “H ow have y ou been feeling since y our l ast visit ?” may be asked. 
Subjects m ay report AEs occurri ng at any  other time during the study . Subjects experi encing an 
SAE before the first exposure to investigational product must be monitored until the symptoms 
subside and any clinically relevant changes in laboratory values have returned to Baseline or there 
is a satisfactory explanat ion for the change. Nonserious AEs that begin before the first exposure to 
investigat ional product, related or unrelated to the study  procedure, need not be fo llowed-up for 
the purposes of the protocol.
All subjects experiencing AEs, whether considered associated with the use of the study medicat ion 
or not, m ust be m onitored until the symptoms subside and any clinically  relevant changes in 
laboratory  values have returned to Baseline or until there is a sat isfactory  explanati on for the 
changes observed. All AEs will be documented in the AE page of the eCRF, whether or not the 
investigator concludes that the event is related to the drug tre atment. The fo llowing informat ion 
will be documented for each event:
Event term .
Start and end date and time.
Pattern of AE (frequency).
Severit y/intensity.
Causalit y (investi gator’s opi nion of the causal relatio nship between the event and 
administration o f study  drug[s]).
Action taken with trial drug.
Outcom e of event.
Seriousness.
10.2.8.3 Reporting SAEs
When an SAE occurs through the AE collection period it should be reported according to the 
procedure outlined below:
TAK -831
TAK -831-1005 Page 53of 84
Protocol Incorporating Amendment No. 02 19 March 2018
CONFIDENTIALA Takeda SAE form must be co mpleted, in Engli sh and signed by the invest igator immediately or 
within 24 hours of first onset or notification of the event. The informat ion should be co mpleted as 
fully as possible but contain, at a minimum:
A short descript ion of the event and the reason why  the event is categorized as serious.
Subject identificat ion number.
Invest igator’s name.
Nam e of the study  medicat ion(s).
Causalit y assessment.
The SAE form should be transmitted within 24 hours to the attention of the contact listed in 
Secti on 14.1.1 .
Any SAE spontaneously reported to the invest igator fo llowing the AE collect ion period should be 
reported to the sponsor if considered related to study  parti cipat ion.
Reporting of SAEs that begin before first administration of investigational product will fo llow the 
same procedure for SAEs occurring on treatment.
SAE Follow -up
If informat ion is not available at the time o f the first report becomes available at a later d ate, the 
investigator should complete a fo llow-up SAE form  or provi de other wri tten docum entati on and 
fax it immediately wit hin 24 hours of receipt. Copies of any relevant data from the hospital notes 
(eg, ECGs, laboratory  tests, di scharge summary, postmor tem resul ts) shoul d be sent to the 
addressee, if requested.
All SAEs should be fo llowed up unt il reso lution or perm anent outcome of the event. The timelines 
and procedure for follow -up reports are the same as those for the init ial report.
10.2.8.4 Reporting Special Interest AEs 
No AEs of special interest have been ident ified for TAK -831.
10.2.8.5 Reporting of Abnormal LFTs
If a subject is noted to have ALT or AST elevated >3×ULN on 2 consecutive occasions, the 
abnorm ality shoul d be recorded as an AE. In addit ion, an LFT Inc reases eCRF must be co mpleted 
provi ding addit ional information on relevant recent history , risk factors, clinical signs and 
symptoms, and results of any  addi tional diagnosti c tests perform ed.
If a subject is noted to have ALT or AST >3×ULN and total biliru bin >2×ULN for which an 
alternat ive etio logy has not been i dentified, the event should be recorded as an SAE and reported 
as per Secti on 10.2.8.3 . The i nvest igator must contact the Medical Monitor for discussio n of the 
relevant subject details and possible alternative etiologies, such as acute viral hepat itis A or B or 
other acute liver disease. Follow -up laboratory  tests as described in Section 9.2.9 must also be 
TAK -831
TAK -831-1005 Page 54of 84
Protocol Incorporating Amendment No. 02 19 March 2018
CONFIDENTIALperform ed. In addi tion, an LFT Increases eCRF must be completed and transmitted with the 
Takeda SAE form (as per Section 10.2.9 ). 
10.2.9 Safety Reporting to Investigators, IRBs or IECs, and Regulatory Authorities 
The sponsor will be responsible for reporting all suspected unexpected serious adverse react ions 
(SUSAR s) and any other applicable SAEs to regulatory  authori ties, invest igators and IRBs or 
IECs, as applicable, in accordance with nat ional regulat ions in the countries where the study  is 
conducted. Relat ive to the first awareness of the event by/or further pro visio n to the sponsor or 
sponsor’s designee, SUSARs will be submitted within 7 days for fatal and life -threatening events 
and 15 days for other serious events, unless otherwise required by nat ional regulat ions. The 
sponsor will also prepare an expedited re port for other safet y issues where these might materially 
alter the current benefit -risk assessment of an investigat ional medicinal product or that would be 
sufficient to consider changes in the investigat ional medicinal products administration or in the 
overall conduct of the trial. The invest igational site also will forward a copy  of all expedited 
reports to his or her IRB or IEC in accordance wit h national regulat ions.
TAK-831
TAK-831-1005 Page 55 of 84
Protocol Incorporating Amendment No. 02 19 March 2018
CONFIDENTIAL11.0 STATISTICAL METHODS
11.1 Statistical and Analytical Plans
A statistical analysis plan will be prepa red and finalized before unblinding of treatment 
assignments. This document will provide further details regarding the definition of analysis 
variables and analysis methodology to address all study objectives.
A blinded targeted data review will be conducted be fore the database lock for the entire study. This 
review will assess the accuracy and completeness of the study database, subject evaluability, and 
appropriateness of the planned statistical methods.
For analyses where baseline and/or change from baseline will be evaluated, the baseline is defined 
as the last available results prior to first dose of study drug except for  parameters. For 
 parameters, the baseline is defined as the average of the 3 measurements (average of 
triplicate measurements) on Day -1 at time points that are matched with those on Day 1.
11.1.1 Analysis Sets
11.1.1.1 Safety Set
The safety set will include all randomized subjects who receive at least 1 dose of study medication. 
Subjects in this analysis set will be used for demographic, baseline characteristics, and safety 
summaries.
11.1.1.2 PK Set
The PK set will include all randomized subjects who receive at least one dose of study medication and 
who have any available plasma concentration data .
11.1.1.3 PD Set
The PD set will consist of all subjects who receive at least 1 dose of study drug and have at least 1 
postdose PD result.
If any subject is found to be noncompliant with the dosing schedule or has incomplete data, a 
decision will be made on a case-by-case basis as to  whether that subject should be included in the 
PK and PD analyses; however, data for all subjects will be presented in the data listings.
11.1.2 Analysis of Demography and Other Baseline Characteristics
Demographic and baseline characteristics will be summarized for subjects in the safety set by 
pooled placebo, each TAK-831 dose level, summary statistics (number of subjects, mean, SD, 
median, minimum, and maximum) will be presented for continuous variables (age, weight, and 
BMI), and the number and percentage of sub jects within each category will be presented for 
categorical variables (sex, ethnicity, and race).
Individual subject demographic and baseline characteristic data will be listed. Demographic 
variables of screen failure subjects and reasons for screen failures will be summarized overall for CCI
CCI
TAK-831
TAK-831-1005 Page 56 of 84
Protocol Incorporating Amendment No. 02 19 March 2018
CONFIDENTIALsubjects who are screened but not enrolled in the study. Individual demographic characteristics, 
date of informed consent, and reason for screen failure will be listed.
11.1.3 PK Analysis
Concentrations of TAK-831 in plasma (all cohorts) and CSF (CSF Cohort[s]) will be summarized 
by dose, drug formulation, and day over each scheduled sampling time using descriptive statistics. 
Individual plasma concentration data versus  time will be presented  in a d ata listing. 
PK parameters of TAK-831 will be derived using noncompartmental analysis methods. The PK 
parameters of TAK-831 will be determined from the concentration-time data for all evaluable 
subjects. Actual sampling times, rather than scheduled sampling times, will be used in all 
computations involving sampling times. Plasma and CSF PK parameters, including 
dose-normalized C maxand AUCs, will be summarized by dose, drug formulation, and day using 
descriptive statistics. Changes in the PK parameters from Day 1 to Day 16 will be assessed by 
summarizing the ratio of Day 16 to Day 1 by dose and drug formulation. Dose proportionality in 
plasma PK parameters (C maxand AUCs) will be assessed graphically for Day 1 and Day 16 plasma 
concentrations for each formulation. Additional  analyses will be in cluded if appropriate.
11.1.4 PD Analysis
11.1.5 Safety Analysis
The safety set will be used for all summaries of safety parameters. Summaries will be presented by 
pooled placebo, each TAK-831 dose level, drug formulation, TAK-831 overall, and overall.
11.1.5.1 AEs
All AEs will be coded by system organ class (SOC) and preferred term (PT) using the Medical 
Dictionary for Regulatory Activities (MedDRA). TEAEs with onset occurring within 30 days 
(onset date – last date of dose +1 ≤30) after study drug administration will be included in the 
summary tables. All AEs will be in the listings. TEAEs will be summarized by SOC and PT. The 
following summary tables will be included in the report: summary of TEAEs and drug-related 
AEs, relationship of AEs to study drug (related vs not related), severity of AEs, and related AEs. CCI
TAK-831
TAK-831-1005 Page 57 of 84
Protocol Incorporating Amendment No. 02 19 March 2018
CONFIDENTIALData listings will be provided for all AEs including TEAEs, AEs leading to study drug 
discontinuation, and SAEs.
11.1.5.2 Clinical Laboratory Evaluation
Individual results of laboratory tests from he matology, chemistry, and urinalysis that meet 
Takeda’s markedly abnormal criteria will be summarized and provided in the data listings. 
Baseline, postdose, and change from Baseline to postdose laboratory data will be summarized. All 
clinical laboratory data will be provided in the data listings.
11.1.5.3 Vital Signs
Individual results of vital signs that meet Takeda’s markedly abnormal criteria will be summarized 
and provided in the data listings. Baseline, postdose, and changes from Baseline in vital sign 
measurements will be summarized. All vital sign data will be provided in the data listings.
11.1.5.4 ECGs
Individual results of quantitative ECG parameter s from the 12-lead safety ECGs that meet 
Takeda’s markedly abnormal criteria will be summarized and provided in the data listings. 
Baseline, postdose, and changes from Baselin e in quantitative ECG parameters will be 
summarized. Shift tables will be generated to show the investigator’s ECG interpretations at each 
postdose collection by the interpretation at Baseline. All ECG data will be provided in the data 
listings.
11.1.5.5 Other Safety Parameters
Physical and neurological examination findings and suicidality assessments (C-SSRS) will be 
presented in data listings.
11.2 Interim Analysis and Criteria for Early Termination
No formal interim analysis is planned. As described in Section  6.2, specific Takeda personnel 
listed in associated study documentation may be unblinded to analyze data considered necessary to 
determine subsequent doses and cohort management decisions during the conduct of the study. In 
addition, sponsor may perform preliminary analy sis to inform dose selection for future 
development.
11.3 Determination of Sample Size
The sample size chosen of 8 subjects for all Cohorts (6 active:2 placebo) is considered to be 
sufficient for evaluation of safety, tolerability, and PK of each cohort to determine the dose for the 
next cohort. The sample size was not based on statistical power considerations.CCI
TAK -831
TAK -831-1005 Page 58of 84
Protocol Incorporating Amendment No. 02 19 March 2018
CONFIDENTIAL12.0 QUALITY CONTROL AND QUALITY ASSURANCE
12.1 Study -Site Monitoring Visits
Moni toring visits to the study  site will  be made peri odically  during the study  to ensure that all 
aspects of the protocol are fo llowed. Source documents will be reviewed for verificat ion of data 
recorded on the eCRFs. Source documents are defined as original documen ts, data, and records. 
The invest igator and study site guarantee access to source documents by the sponsor or its 
designee (contract research organization) and by the IRB or IEC.
All aspects of the study  and i ts docum entati on will be subject to review by t he sponsor or the 
sponsor’s designee (as long as blinding is not jeopardized), including but not limited to the 
Invest igator’s Binder, trial drug, subject medical records, informed consent documentation, and 
review of eCRFs and associated source documents. It is important that the invest igator and other 
study  personnel are available during the monitoring visits and that sufficient time is devoted to the 
process.
12.2 Protocol Deviations
The invest igator should not deviate fro m the protocol , except where necessar y to eliminate an 
immediate hazard to trial subjects. Should other unexpected circumstances arise that will require 
deviat ion from protocol -specified procedures, the investigator should consult with the sponsor or 
designee (and IRB or IEC, as required) to determine the appropriate course of action. There will be 
no exempt ions (a prospectively approved deviat ion) from the inclusio n or exclusio n criteria.
Significant deviat ions include, but are not limited to, those that invo lve fraud or misconduct, 
increase the healt h risk to the subject, or confound interpretation of primary study  assessment. 
12.3 Quality Assurance Audits and Regulatory Agency Inspections
The study  site also m ay be subject to qualit y assurance audi ts by  the sponsor or desi gnees. In this 
circumst ance, the sponsor -designated audi tor will  contact the si te in advance to arrange an 
auditing visit. The auditor may ask to visit the facilit ies where laboratory  samples are collected, 
where the medication is stored and prepared, and any other facilit y used during the study . In 
addition, there is the possibilit y that this study may be inspected by regulatory agencies, including 
those of foreign governments (eg, the Food and Drug Administration, the United Kingdo m 
Medicines and Healt hcare products Regulatory Agency, the Pharmaceut icals and Medical Devices 
Agency o f Japan). If the study site is contacted for an inspect ion by a regulatory body, the sponsor 
shoul d be notified immediately. The invest igator guarantees access for qualit y assurance auditors 
to all st udy docum ents as described in Section 12.1.
TAK -831
TAK -831-1005 Page 59of 84
Protocol Incorporating Amendment No. 02 19 March 2018
CONFIDENTIAL13.0 ETHICAL ASPECTS OF T HE STUDY
This study  will be conducted wi th the highest respect for the individual participants (ie, subjects) 
according to the protocol, the ethical principles that have their origin in the Declaration o f 
Helsinki, and the International Conference on Harmo nisat ion (ICH) Harmonised Tripartite 
Guideline for GCP. Each investigator will conduct the study  according to applicable local or 
regional regulatory  requi rements and align his or her conduct in accordance wit h the 
“Responsibilit ies of the Investigator” that are listed in Appendix A. The principles of Helsinki are 
addressed through the protocol and through appendices containing requirements for informed 
consent and invest igator responsibilit ies.
13.1 IRB and/or IEC Approval
IRBs and IECs must be constituted according to the applicable state and federal/local requirements 
of each participat ing regio n. The sponsor or designee will require documentation noting all names 
and tit les of members who make up the respective IRB or IEC. If any member of the IRB or IEC 
has di rect part icipation in this study , written notification regarding his or her abstinence fro m 
voting must also be obtained. Those Americas sites unwilling to provide names and tit les of all 
members because of privacy and conflict of interest concerns should instead p rovide a Federal  
Wide Assurance Number or comparable number assigned by the Department of Health and 
Hum an Services.
The sponsor or designee will supply relevant documents for submissio n to the respective IRB or 
IEC for the protocol’s review and approval. This protocol , the Invest igator’s Brochure, a copy o f 
the informed consent form, and, if applicable, subject recruit ment materials and/or advertisements 
and other documents required by all applicable laws and regulations, must be submitted to a 
central  or local IRB or IEC for approval. The IRB’s or IEC’s written approval of the protocol and 
subject informed consent must be obtained and submitted to the sponsor or designee before 
commencement of the study  (ie, before shipment of the sponsor -supplied drug or study specific 
screening activit y). The IRB or IEC approval must refer to the study  by exact protocol tit le, 
number, and versio n date; ident ify versio ns of other documents (eg, informed consent form) 
reviewed; and state the approval date. The sponsor will ship drug/notify  site once the sponsor has 
confirmed the adequacy of site regulatory  docum entati on and, when applicable, the sponsor has 
received permissio n from competent authori ty to begin the trial. Unt il the site receives 
drug/notificat ion no protocol activit ies, including screening, may occur.
Sites m ust adhere to all requirements stipulated by  their respect ive IRB or IEC. This may include 
notification to the IRB or IEC regarding protocol amendments, updates to the informed consent 
form, recrui tment m aterials intended for viewing by  subjects, l ocal safety  reporti ng requirements, 
reports and updates regarding the ongoing review of the study  at intervals specified by  the 
respective IRB or IEC, and submissio n of the investigator’s final status report to IR B or IEC. All 
IRB and IEC approvals and relevant documentation for these items must be provided to the 
sponsor or its designee.
Subject incentives should not exert undue influence for participat ion. Payments to subjects must 
be approved by the IRB or IEC a nd sponsor.
TAK -831
TAK -831-1005 Page 60of 84
Protocol Incorporating Amendment No. 02 19 March 2018
CONFIDENTIAL13.2 Subject Information, Informed Consent, and Subject Authorization
Written consent documents will embody  the elements of informed consent as described in the 
Declaration of Helsinki and the ICH Guidelines for GCP and will be in accordance with al l 
applicable laws and regulations. The informed consent form, subject authorizat ion form (if 
applicable), and subject informat ion sheet (if applicable) describe the planned and permitted uses, 
transfers, and disclo sures of the subject’s personal and person al healt h informat ion for purposes of 
conducting the study. The informed consent form and the subject informat ion sheet (if applicable) 
further explain the nature of the study, its object ives, and potential risks and benefit s, as well as the 
date informed consent i s given. The informed consent form will detail the requirements of the 
participant and the fact that he or she is free to withdraw at any  time wi thout giving a reason and 
without prej udice to hi s or her further m edical care.
The invest igator is re sponsible for the preparation, content, and IRB or IEC approval of the 
inform ed consent form  and, if applicable, the subject authorization form. The informed consent 
form, subject authorizat ion form (if applicable), and subject information sheet (if applic able) must 
be approved by both the IRB or IEC and the sponsor before use.
The informed consent form, subject authorizat ion form  (if applicable), and subject informat ion 
sheet (if applicable) must be written in a language fully co mprehensible to the prospec tive subject. 
It is the responsibilit y of the invest igator to explain the detailed elements of the informed consent 
form, subject authorizat ion form (if applicable), and subject informat ion sheet (if applicable) to the 
subject. Information should be given in both oral and written form whenever possible and in the 
manner deemed appropriate by the IRB or IEC. In the event the subject is not capable of rendering 
adequate written informed consent, then the subject’s legally  acceptable representative may 
provi desuch consent for the subject in accordance with applicable laws and regulat ions.
The subject, or the subject’s legally acceptable representative, must be given ample opportunit y to: 
(1) inquire about details o f the study, and (2) decide whether or not to participate in the study. If the 
subject, or the subject’s legally acceptable representative, determines he or she will part icipate in 
the study , then the informed consent form and subject authorizat ion form (if applicable) m ust be 
signed and dated by  the subject, or the subject’s legally acceptable representative, at the time of 
consent and before the subject entering into the study . The subject or the subject’s legally 
acceptable representative should be instructed to sign using their legal names, not nic knames, 
using blue or black ballpo int ink. The invest igator must also sign and date the informed consent 
form and subject authorizat ion (if applicable) at th e time of consent and before subject entering 
into the study; however, the sponsor may  allow a desi gnee of the invest igator to sign to the extent 
permitted by  applicable law.
Once signed, the original informed consent form, subject authorization form (if applicable), and 
subject informat ion sheet (if applicable) will be stored in the invest igator’s site file. The 
investigator must document the date the subject signs the informed consent in the subject’s 
medical record. Copies of the signed informed consent form, the signed subject authorization for m 
(if applicable), and subject informat ion sheet (if appl icable) shall be given to the subject.
TAK -831
TAK -831-1005 Page 61of 84
Protocol Incorporating Amendment No. 02 19 March 2018
CONFIDENTIALAll revised informed consent forms must be reviewed and signed by relevant subjects or the 
relevant subject’s legally  acceptable representative in the same manner as the original informed 
consent. The date the revised consent was ob tained shoul d be recorded in the subject’s medical 
record, and the subject should receive a copy  of the revised informed consent form.
Subjects who consented and provided a PGx sample for DNA analysis can wit hdraw their consent 
and request d isposal o f a stored sample at any  time before analysis. Notify sponsor of consent 
withdrawal .
13.3 Subject Confidentiality
The sponsor and designees affirm and uphol d the principle of the subject’s right to protection 
against invasio n of privacy. Throughout thi s study , a subject’s source data will only be linked to 
the sponsor’s clinical study  database or documentation via a unique ident ificat ion number. As 
permitted by all applicable laws and regulat ions, limited subject attributes, such as sex, age, or date 
ofbirth, and subject init ials may be used to verify the subject and accuracy o f the subject’s unique 
ident ificat ion number.
To com ply with ICH Guidelines for GCP and to verify co mpliance with this protocol, the sponsor 
requi res the investigator to permit it s monitor or desi gnee’s m onitor, representatives from  any 
regul atory  authori ty (eg, FDA, Medi cines and Heal thcare products Regul atory  Agency, 
Pharmaceut icals and Medical Devices Agency), the sponsor’s designated auditors, and the 
appropriate IRBs and IECs to revi ew the subject’s original medical records (source data or 
docum ents), including, but not limited to, laboratory  test resul t reports, ECG reports, admissio n 
and discharge summaries for hospital admissio ns occurring during a subject’s study participat ion, 
and autopsy  reports. Access to a subject’s original medical records requires the specific 
authori zation of the subject as part of the informed consent process (see Section 13.2).
Copi es of  any subject source documents that are provided to the sponsor must have certain 
personally ident ifiable informat ion rem oved (ie, subject name, address, and other ident ifier fields 
not collected on the subject’s e CRF).
13.4 Publication, Disclosure, and Clinical Trial Registration Policy
13.4.1 Publication and Disclosure
The investigator is obliged to provide the sponsor with complete test results and all data derived by 
the invest igator from the study . During and after the stu dy, only the sponsor may make study  
inform ation available to other study  invest igators or to regulatory  agencies, except as required by  
law or regul ation. Except as otherwise allowable in the clinical study  site agreement, any  public 
disclosure (including publicly accessible websites) related to the protocol or study  resul ts, other 
than study  recrui tment m aterials and/or advertisements, is the sole responsibilit y of the sponsor.
The sponsor may publish any data and informat ion fro m the study (including data and informatio n 
generated by  the invest igator) without the consent of the invest igator. Manuscript authorship for 
any peer -reviewed publicat ion will appropriately reflect contribut ions to the production and 
review of the document. All publicat ions and pre sentati ons must be prepared in accordance with 
TAK -831
TAK -831-1005 Page 62of 84
Protocol Incorporating Amendment No. 02 19 March 2018
CONFIDENTIALthis secti on and the Clinical Study  Site Agreement. In the event of any discrepancy  between the 
protocol  and the Clinical Study  Site Agreement, the Clinical Study  Site Agreement will prevail.
13.4.2 Clinical Trial Re gistration 
In order to ensure that informat ion on clinical trials reaches the public in a timely manner and to 
comply with applicable laws, regulat ions and guidance, Takeda will, at a minimum register all 
intervent ional clinical tri als it sponsors anywher e in the worl d on ClinicalTrials.gov and/or other 
publicly  accessible websites before start of study , as defined in Takeda Policy/Standard . Takeda 
contact informat ion, along wit h invest igator’s cit y, state (for Americas investigators), country, and 
recrui ting status will be registered and available for public viewing. 
For some registries, Takeda will assist callers in lo cating study  sites cl osest to thei r homes by 
provi ding the invest igator name, address, and phone number to the callers request ing trial 
information. Once subjects receive invest igator contact informat ion, they  may call  the si te 
requesting enrollment into the trial. The invest igative sites are encouraged to handle the trial 
inquiries according to their established subject screening process. I f the caller asks addit ional 
questions bey ond the topic of trial enro llment, they should be referred to the sponsor.
Any invest igator who objects to the sponsor providing this informat ion to callers must provide the 
sponsor with a written notice request ingthat thei r inform ation not be listed on the registry  site.
13.4.3 Clinical Trial Results Disclosure 
Takeda will post the results of clinical trials on ClinicalTrials.gov or other publicly accessible 
websites, as required by Takeda Policy/Standard, applicable la ws and/or regul ations.
13.5 Insurance and Compensation for Injury
Each subject in the study  must be insured in accordance with the regulations applicable to the site 
where the subject is participat ing. If a local underwriter is required, then the sponsor or spo nsor’s 
designee will obtain clinical study  insurance against the risk o f injury to study  subjects. Refer to 
the study site agreement regarding the sponsor’s policy on subject compensat ion and treatment for 
injury . If the invest igator has questions regardin g this policy, he or she should contact the sponsor 
or sponsor’s designee.
TAK-831
TAK-831-1005 Page 63 of 84
Protocol Incorporating Amendment No. 02 19 March 2018
CONFIDENTIAL14.0 ADMINISTRATIVE AND REFERENCE INFORMATION
14.1 Administrative Information
14.1.1 Study Contac t Information 
Contact Type / Role Contact
SAE and pregnancy reporting PPD
TAK -831
TAK -831-1005 Page 64of 84
Protocol Incorporating Amendment No. 02 19 March 2018
CONFIDENTIAL14.1.2 INVESTIGATOR AGREEMENT 
I confirm that I have read and that I understand this protocol, the Invest igator’s Brochure, package 
insert and any  other product information provided by  the sponsor. I agree to conduct this study  in 
accordance with the requirements of this protocol and also to protect the rights, safet y, privacy, 
and well -being o f study  subjects in accordance with the following:
The ethical principles that have their origin in the Declaration of Helsinki.
ICH, E6 GCP: Consolidated Guideline.
All applicable laws and regulat ions, including, without limitat ion, data privacy laws and 
regul ations.
Regulatory  requi rements for reporting SAEs defined in Section 10.2.9 of this protocol .
Terms outlined in the study  site agreement.
Responsibilit ies o f the Invest igator ( Appendix A).
I further authorize that my  personal informat ion may be processed and transferred in accordance 
with the uses contem plated in Appendix Cof this protocol .
Signature of Investigator Date
Invest igator Name (print or ty pe)
Invest igator’s Tit le
Locati on of  Facilit y (Ci ty, State/Provence)
Locati on of  Facilit y (Country )
TAK -831
TAK -831-1005 Page 65of 84
Protocol Incorporating Amendment No. 02 19 March 2018
CONFIDENTIAL14.1.3 Study -Related Responsibilities 
The sponsor will perform all study -related activit ies wi th the except ion of those i dentified in the 
Study -Related Responsibilit ies template. The vendors i dentified for specific study -related 
activit ies will perf orm these act ivities in full or in partnership wi th the sponsor.
14.1.4 List of Abbreviations
AE adverse event
ALT alanine aminotransferase
anti-HCV antibody to hepatitis C virus
AST aspartate aminotransferase
AUC area under the plasma concentration -time curve
AUC 24 area under the plasma concentration -time curve from 0 to 24 hours
AUC τ area under the plasma concentration -time curve during a dosing interval, where tau (τ) is the length 
of the dosing interval
BID twice daily
BMI body mass index
Cav,ss average plasma concentration at steady state
CFR Code of Federal Regulations
CIAS cognitive impairment associated with schizophrenia
Cmax maximum observed plasma concentration
Cmax CSF maximum observed CSF concentration
CNS central nervous system
CS clinically significant
CSF cerebrospinal fluid
C-SSRS Columbia –Suicide Severity Rating Scale 
DAO D-amino acid oxidase
ECG electrocardiogram
eCRF electronic case report form
Emax maximum drug -induced effect
FDA Food and Drug Administration
FSH follicle stimulating hormone 
GCP Good Clinical Practice
HBsAg hepatitis B surface antigen
hCG human chorionic gonadotropin
HIV human immunodeficiency virus
ICH International Conference on Harmonisation
IEC Independent Ethics Committee
INR internatio nal no rmalized ratio
IRB institutional review board
TAK -831
TAK -831-1005 Page 66of 84
Protocol Incorporating Amendment No. 02 19 March 2018
CONFIDENTIALLFT liver function test
MD multiple dose
MedDRA Medical Dictionary for Regulatory Activities
MRD multiple rising dose
NCS not clinically significant
NMDA N-methy l-D-aspartate
NOAEL no-observed -adverse -effect level
NSS negative symptoms of schizophrenia
PD pharmacodynamics
PGx pharmacogenomics
PK pharmacokinetic
PT preferred term
QD once daily
QTc corrected QT (interval)
QTcF QT interval with Frederica correction method
SAE serious adverse event
SOC system organ class
SUSAR suspected unexpected serious adverse reactions
TEAE treatment -emergent adverse event
ULN upper limit of normal
TAK -831
TAK -831-1005 Page 67of 84
Protocol Incorporating Amendment No. 02 19 March 2018
CONFIDENTIAL15.0 DATA HANDLING AND RE CORDKEEPING
The full details of procedures for data handling will be docum ented in the Data Management Plan. 
AEs, m edical history , and concurrent conditions will be coded using the MedDRA. Drugs will be 
coded using the World Healt h Organizat ion Drug Di ctionary.
15.1 CRFs (Electronic and Paper)
Com pleted eCRFs are required for ea ch subject who signs an informed consent.
The sponsor or its designee will supply investigative sites with access to eCRFs. The sponsor will 
make arrangements to train appropriate site staff in the use of the eCRF. These forms are used to 
transmit the info rmation collected in the performance o f this study  to the sponsor and regulatory  
authori ties. eCRFs must be completed in English. Data are transcribed direct ly onto eCRFs.
After complet ion of the entry process, computer logic checks will be run to identify items, such as 
inconsistent dates, missing data, and questionable values. Queries may be issued by Takeda 
personnel (or designees) and will be answered by the site. 
Correcti ons are recorded i n an audit trail that captures the old informat ion, the new inf ormation, 
ident ificat ion of the person making the correction, the date the correction was made, and the reason 
for change. Reasons for si gnificant correcti ons shoul d addi tionally be included. 
The principal invest igator must review the eCRFs for completene ss and accuracy  and must si gn 
and date the appropriate eCRFs as indicated. Furthermore, the investigator must retain full 
responsibilit y for the accuracy  and authent icity of all data entered on the eCRFs .
After the lock of the clinical study database, any change of, modificat ion of, or addit ion to the data 
on the eCRFs should be made by the investigator with use of change and modificat ion records of 
the eCRFs. The principal investigator must review the data change for completeness and accuracy, 
and must sig n and date . 
eCRFs will be reviewed for completeness and acceptabilit y at the study  site during peri odic visi ts 
by study  monitors. The sponsor or i ts designee will be permitted to review the subject’s medical 
and hospital records pertinent to the study to ensure accuracy of the eCRFs. The completed eCRFs 
are the sole property  of the sponsor and should not be made available in any form to third parties, 
except for authorized representatives of appropriate governmental healt h or regulatory authorities, 
without written permissio n of the sponsor.
15.2 Record Retention
The invest igator agrees to keep the records stipulated in Section 15.1 and those documents that
include (but are not limited to) the study -specific documents, the ident ificat ion log of all 
participat ing subjects, medical records, temporary media such as thermal sensit ive paper, source 
worksheets, all original signed and dated informed consent forms, subject authorizat ion forms 
regarding the use of personal healt h information (if separate from the informed consent forms), 
electroni c copy  of eCRFs, incl uding the audi t trail, and detailed records of drug disposit ion to 
enable evaluat ions or audits from regulatory  authori ties, the sponsor or its designees. Any  source 
TAK -831
TAK -831-1005 Page 68of 84
Protocol Incorporating Amendment No. 02 19 March 2018
CONFIDENTIALdocum entati on printed on degradable thermal sensitive paper should be photocopied by the site 
and filed wit h the original in the subject’s chart to ensure long -term legibilit y. Furthermore, I CH 
E6 Secti on 4.9.5 requi res the investigator to retain essent ial docum ents specified in ICH E6 
(Secti on 8) until at least 2 y ears after the last approval of a market ing applicat ion for a specified 
drug indicat ion being investigated or, if an applicatio n is not approved, until at least 2 years after 
the invest igation is discontinued and regulatory authorities are notified. In addit ion, ICH E6 
Secti on 4.9.5 states that the study  records should be retained unt il an am ount of time specified by  
applicable regul atory  requi rements or for a time specified in the Clinical Study  Site Agreement 
between the invest igator and sponsor.
Refer to the Clinical Study Site Agreement for the sponsor’s requirements on record retention. The 
investigator and the head of the instit ution shoul d contact and receive written approval fro m the 
sponsor before disposing of any  such documents.
TAK -831
TAK -831-1005 Page 69of 84
Protocol Incorporating Amendment No. 02 19 March 2018
CONFIDENTIAL16.0 REFERENCES
1.Verrall L, Burnet PW, Betts JF, Harrison PJ. The neurobiology of D -amino acid oxidase and its 
involvement in schizoph renia. Mo l Psychiatry 2010;15(2):122 -37.
2.Kakegawa W, Miyoshi Y, Hamase K, Matsuda S, Matsuda K, Kohda K, et al. D -serine 
regul ates cerebellar LTD and motor coordination through the delta2 glutamate receptor. Nat 
Neurosci 2011;14(5):603-11.
3.Krystal JH, D'Souza DC, Mathalon D, Perry  E, Belger A, Hoffman R. NMDA receptor 
antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift  
in medicat ion development. Psychopharmaco logy (Berl ) 2003;169(3- 4):215 -33.
4.Calcia MA, Madeira C, Alheira FV, Silva TC, Tannos FM, Vargas -Lopes C, et al. Plasma 
levels o f D-serine in Brazilian individuals wit h schizophrenia. Schizophr Res 
2012;142(1 -3):83 -7.
5.Ohnuma T, Sakai Y, Maeshima H, Hatano T, Hanzawa R, Abe S, et al. Changes in plas ma 
glycine, L -serine, and D -serine levels in pat ients with schizophrenia as their clinical symptoms 
improve: results from the Juntendo Universit y Schizophrenia Proj ects (JUSP). Prog 
Neuropsychopharmaco l Biol Psychiatry  2008;32(8):1905 -12.
6.Hashimoto K, F ukushima T, Shimizu E, Ko matsu N, Watanabe H, Shinoda N, et al. Decreased 
serum  levels of D -serine in pat ients with schizophrenia: evidence in support of the 
N-methyl-D- aspartate receptor hy pofunction hypothesis of schizophrenia. Arch Gen 
Psychiatry  2003;6 0(6):572 -6.
7.Hashimoto K, Engberg G, Shimizu E, Nordin C, Lindstrom LH, Iy o M. Reduced D -serine to 
total serine rati o in the cerebrospinal fluid o f drug naive schizophrenic pat ients. Prog 
Neuropsychopharmaco l Biol Psychiatry  2005;29(5):767 -9.
8.Schizoph renia Working Group of the Psy chiatri c Geno mics Consortium. Bio logical insights 
from 108 schizophrenia- associ ated genet ic loci. Nature 2014;511(7510):421-7.
9.Lane HY, Lin CH, Green MF, Hellemann G, Huang CC, Chen PW, et al. Add -on treatm ent of 
benzoate f or schizophrenia: a rando mized, double -blind, pl acebo -controlled trial o f D-amino 
acid oxidase inhibitor. JAMA Psychiatry  2013;70(12):1267 -75.
10.Posner K, Brent D, Lucas C, Gould M, Stanley B, Brown G, et al. Co lumbia -suicide severit y 
rating scale (C -SSRS). Columbia Universit y. Updated 14 January 09. Accessed 01 May 2012. 
Available at: http://www.cssrs.columbia.edu/docs/C -SSRS_1_14_09_Since_Last_Visit.pdf.
11.Posner K, Oquendo MA, Gould M, Stanley B, Davies M. Columbia Classificat ion Algorithm 
of Suicide Assessment (C -CASA): classificat ion of suicidal events in the FDA's pediatric 
suicidal risk analysis of ant idepressants. Am J Psychiatry 2007;164(7):1035-43.
TAK -831
TAK -831-1005 Page 70of 84
Protocol Incorporating Amendment No. 02 19 March 2018
CONFIDENTIAL17.0 APPENDICES
Appendix AResponsibilities of the Investigator
Clinical research studies sponsored by  the sponsor are subject to ICH GCP and all the applicable 
local laws and regulat ions. The responsibilit ies imposed on invest igators by  the FDA are 
summarized in the “Statement of Invest igator” (Form FDA 1572), which m ust be com pleted and 
signed before the invest igator may participate in this study .
The invest igator agrees to assume the fo llowing responsibilit ies by signing a Form FDA 1572:
1.Conduct the study  in accordance wit h the protocol.
2.Personally conduct or supervi se the staff that will assist in the protocol.
3.If the invest igator/institution retains the services of any individual or party to perform 
trial-related duti es and funct ions, the invest igator/inst itution shoul d ensure that this individual 
or party  is qualif ied to perform those trial -related duti es and funct ions and should implement 
procedures to ensure the integrit y of the tri al-related duti es and funct ions performed and any 
data generated.
4.Ensure that study  related procedures, including study  specific (nonr outine/nonstandard panel) 
screening assessments are NOT performed on potent ial subjects, before the receipt of written 
approval  from relevant governing bodies/authorit ies.
5.Ensure that all co lleagues and emplo yees assist ing in the conduct of the study are i nformed of 
these obligat ions.
6.Secure prior approval o f the study and any changes by an appropriate IRB/IEC that conform to 
21 Code of Federal Regulations (CFR) Part 56, ICH, and local regulatory  requi rements.
7.Ensure that the IRB/IEC will be responsible for initial review, continuing review, and approva l 
of the protocol. Promptly report to the IRB/IEC all changes in research act ivity and all 
anticipated risks to subjects. Make at least y early reports on the progress of the study  to the 
IRB/IEC, and issue a f inal report wi thin 3 m onths of study  com pletion.
8.Ensure that requirements for informed consent, as outlined in 21 CFR Part 50, ICH and local 
regul ations, are m et.
9.Obtain valid informed consent from each subject who participates in the study , and docum ent 
the date of consent in the subject’s medical chart. Valid informed consent is the most current 
versio n approved by the IRB/IEC. Each informed consent form should contain a subject 
authori zation sect ion that describes the uses and disclosures of a subject’s personal 
inform ation (including personal health informat ion) that will take place in connect ion wit h the 
study . If an informed consent form does not include such a subject authorization, then the 
investigator must obtain a separate subject authorization fo rm from each subject or the 
subject’s legally acceptable representative.
10.Prepare and maintain adequate case histories of all persons entered into the study , incl uding 
eCRFs, hospital records, laboratory  resul ts, etc, and maintain these data for a minimum o f 
TAK -831
TAK -831-1005 Page 71of 84
Protocol Incorporating Amendment No. 02 19 March 2018
CONFIDENTIAL2years fo llowing notificat ion by the sponsor that all invest igations have been discont inued or 
that the regulatory  authori ty has approved the marketing applicat ion. The invest igator should 
contact and receive written approval fro m the sponsor before dis posing of any such 
docum ents.
11.Allow possible inspection and copying by the regulatory  authori ty of GCP -specified essent ial 
docum ents.
12.Maintain current records of the receipt, administratio n, and disposit ion of sponsor -supplied 
drugs, and return all unused sponsor -supplied drugs to the sponsor. 
13.Report adverse reactions to the sponsor prompt ly. In the event of an SAE, notify the sponsor 
within 24 hours.
TAK -831
TAK -831-1005 Page 72of 84
Protocol Incorporating Amendment No. 02 19 March 2018
CONFIDENTIALAppendix BElements of the Subject Informed Consent
In seeking informed consent, the fo llowing information shall be provided to each subject:
1.A statement that the study  involves research.
2.An explanat ion of the purposes of the research.
3.The expected duration of the subject’s participat ion.
4.A descript ion of the procedures to be followed, including invasive procedures.
5.The i dentificat ion of any  procedures that are experimental.
6.The est imated number of subjects invo lved in the study .
7.A descript ion of the subject’s responsibilit ies.
8.A descript ion of the conduct of the study .
9.A state ment describing the treatment(s) and the probabilit y for random  assignment to each 
treatm ent.
10.A descript ion of the possible side effects of the treatment that the subject may receive.
11.A descript ion of any  reasonably  foreseeable ri sks or di scomf orts to the subject and, when 
applicable, to an embry o, fetus, or nursing infant.
12.A descript ion of any  benefi ts to the subject or to others that reasonably  may be expected from  
the research. When there is no intended clinical benefit to the subject, the subject should be 
made aware of this.
13.Disclosures o f appropriate alternat ive procedures or courses of treatment, if any, that might be 
advantageous to the subject and their important potent ial risks and benefits.
14.A statement describing the extent to which confident iality of records i dentifying the subject 
will be maintained, and a note of the possibilit y that regul atory  agencies, auditor(s), IRB/IEC, 
and the monitor may inspect the records. By  signing a written informed consent form, the 
subject or the subject’s legally acceptable representative is authorizing such access.
15.For research invo lving more than minimal risk, an explanat ion as to whether any co mpensatio n 
and an explanat ion as to whether any  medical treatments are available if injury  occurs and, if 
so, what they  consist of or where further informat ion may be obtained.
16.The ant icipated prorated payment(s), if any, to the subject for participat ing in the study.
17.The ant icipated expenses, if any , to the subject for parti cipat ing in the study.
18.An explanat ion of whom to contact for answers to pertinent questions about the research 
(invest igator), subject’s rights, and IRB/IEC and who m to contact i n the event of a 
research -related inj ury to the subject.
19.A statement that participation is vo luntary, that refusal to participa te will invo lve no penalt y or 
loss of benefit s to whi ch the subject otherwise is ent itled, and that the subject or the subject’s 
TAK -831
TAK -831-1005 Page 73of 84
Protocol Incorporating Amendment No. 02 19 March 2018
CONFIDENTIALlegally acceptable representative may discont inue participat ion at any  time wi thout penal ty or 
loss of benefit s to whi ch the su bject i s otherwise ent itled.
20.The consequences of a subject’s decisio n to wi thdraw from  the research and procedures for 
orderly terminat ion of part icipation by the subject.
21.A statement that the subject or the subject’s legally acceptable representative will be informed 
in a timely  manner if informat ion beco mes available that may be relevant to the subject’s 
willingness to continue participat ion in the study .
22.A statement that results of PGx analysis will not be disclosed to an individual, unless 
prevailing la ws requi re the sponsor to do so.
23.The foreseeable circumstances or reasons under which the subject’s participat ion in the study  
may be terminated.
24.A wr itten subject authorization (eit her contained within the informed consent form or provided 
as a separate d ocum ent) describing to the subject the contemplated and permissible uses and 
disclosures of the subject’s personal information (including personal health informat ion) for 
purposes of conduct ing the study. The subject authorizat ion must contain the fo llowing 
statements regarding the uses and disclosures of the subject’s personal informat ion:
a)that personal information (including personal healt h informat ion) may be processed by  or 
transferred to other parties in other countries for clinical research and safet yreporti ng 
purposes, including, without limitat ion, to the fo llowing: (1) Takeda, its affiliates, and 
licensing partners; (2) business partners assist ing Takeda, its affiliates, and licensing 
partners; (3) regulatory  agencies and other healt h authorities; and (4) IRBs/IECs;
b)it is possible that personal informat ion (including personal healt h informat ion) may be 
processed and transferred to countries that do not have data protection laws that offer 
subjects the same level o f protecti on as the data protection laws wit hin this country; 
however, Takeda will make every  effort to keep y our personal  information confident ial, 
and y our name will not be di sclosed outsi de the clinic unless required by law;
c)that personal information (including personal healt h informat ion) may be added to 
Takeda’s research databases for purposes of developing a better understanding of the 
safet y and effect iveness o f the study  medicat ion(s), studying other therapies for patients, 
developing a better understanding of disease, and improving t he efficiency of future 
clinical studies;
d)that subjects agree not to restrict the use and disclo sure of their personal informat ion 
(including personal healt h informat ion) upon withdrawal fro m the study  to the extent that 
the restricted use or disclosure of such informat ion may  impact the scient ific integrity of 
the research; and
e)that the subject’s ident ity will remain confident ial in the event that study  resul ts are 
published.
TAK -831
TAK -831-1005 Page 74of 84
Protocol Incorporating Amendment No. 02 19 March 2018
CONFIDENTIAL25.Female subjects of childbearing potential (eg, nonsterilized, premenopausal femal e subjects) 
who are sexually  active m ust use highly  effect ive contraception (as defined in the informed 
consent) from signing the informed consent and throughout the duration of the study , and for 
(5 half -lives PLUS 30 day s) after the l ast dose of study  drug. Regular pregnancy tests will be 
perform ed throughout the study for all female subjects of childbearing potential. If a subject is 
found to be pregnant during study , study  drug will  be discont inued and the invest igator will 
offer the subject the cho ice to receive unblinded treatment informat ion. 
26.Male subjects must use highly effect ive contraceptio n (as defined in the informed consent) 
from signing the informed consent throughout the duration of the study  and f or (5 half -lives 
PLUS 90 days) after the las t dose of study drug. If the partner or wife of the subject is found to 
be pregnant during the study , the invest igator will offer the subject the cho ice to receive 
unblinded treatment informat ion. 
27.A statem ent that clinical trial informat ion fro m this tria l will be publicly disclo sed in a publicly 
accessible website, such as ClinicalTrials.gov.
TAK -831
TAK -831-1005 Page 75of 84
Protocol Incorporating Amendment No. 02 19 March 2018
CONFIDENTIALAppendix CInvestigator Consent to the Use of Personal Information 
Takeda will co llect and retain personal information of invest igato r, including his or her name, 
address, and other personally identifiable informat ion. In addit ion, invest igator’s personal 
inform ation may be transferred to other parties located in countries throughout the world (eg, the 
United Kingdom, United States, and Japan), including the following:
Takeda, its affiliates, and licensing partners.
Business partners assist ing Takeda, its affiliates, and licensing partners.
Regulatory  agencies and other health authorit ies.
IRBs and IECs.
Invest igator’s personal informat ion may  be retained, processed, and transferred by  Takeda and 
these other parties for research purposes including the fo llowing:
Assessment of the suitabilit y of invest igator for the study  and/or other clinical studies.
Management, monitoring, inspect ion, and audit of the study .
Analysis, review, and verificat ion of the study  results.
Safety reporti ng and pharmacovigilance relat ing to the study .
Preparati on and submissio n of regulatory  filings, correspondence, and communicat ions to 
regul atory  agencies rel ating to the study .
Preparati on and submissio n of regulatory  filings, correspondence, and communicat ions to 
regul atory  agencies relat ing to other medications used in other clinical studies that may contain 
the sam e chemical com pound present in the study  medication.
Inspect ions and invest igations by regulatory  authorit ies relat ing to the study.
Self-inspect ion and internal audit within Takeda, its affiliates, and licensing partners.
Archiving and audit of study  records.
Posting invest igator site contact informa tion, study details and results on publicly  accessible 
clinical trial registries, databases, and websites.
Invest igator’s personal informat ion may be transferred to other countries that do not have data 
protecti on laws that offer the same level of protecti on as data protection laws in invest igator’s own 
country .
Invest igator acknowledges and consents to the use of his or her personal information by Takeda 
and other parties for the purposes described above.
TAK -831
TAK -831-1005 Page 76of 84
Protocol Incorporating Amendment No. 02 19 March 2018
CONFIDENTIALAppendix DPregnancy and Contraception
Contraception and Pregnancy Avoidance Procedure
Male Subjects and Their Female Partners
From  signing of informed consent, throughout the duration of the study , and for (5 half -lives 
PLUS 90 day s, which for TAK -831 is 95 days) after last dose of study drug, nonsterilized** male 
subjects who are sexually act ive with a female partner of childbearing potential* must use barrier 
contraception (eg, condom with or without spermicidal cream or jelly). In addit ion, they  must be 
advised not to dona te sperm during this period. Females partners of childbearing potential who are 
partners of male subjects are also advised to use addit ional contraception as shown in the list 
containing highly effective/effect ive contraception below.
In studies wit h no risk of fetotoxicit y/teratogenici ty/genotoxi city: male subjects are not required to 
use barrier contraception.
Female Subjects and Their Male Partners
From  signing of informed consent, throughout the duration of the study , and for (5 half -lives 
PLUS 30 days, which for TAK -831 is 35 day s) after last dose of study  drug, female subjects of 
childbearing potential* who are sexually act ive wit h a nonsterilized male partner** must use a 
highly  effect ive/effect ive method of contraception (fro m the list below). 
For s tudies in which teratogenicit y/genotoxi city/embry otoxi city has been demo nstrated (IMP or 
comparator or background medicat ion), or there is a lack of adequate reproductive toxicit y data, 
female subjects should be instructed to use two highly effect ive metho ds of contraception/one 
highly  effect ive and one effect ive method (fro m the list below). 
In addit ion they  must be advised not to donate ova during this period.
Definitions and Procedures for Contraception and Pregnancy Avoidance
The follow ing definitions apply for contraception and pregnancy avoidance procedures.
* A wom an is considered a woman of childbearing potential, that is, fertile, fo llowing menarche 
and until beco ming post -menopausal unless permanent ly sterile. Permanent sterilizat ion methods 
inclu de hysterectomy , tubal  ligat ion, and bilateral oophorectomy . A postm enopausal  state i s 
defined as no menses for 12 months wit hout an alternat ive medical cause. A high FSH level in the 
postm enopausal  range (FSH >40 IU/L) may be used to confirm a postmenopau sal state in younger 
wom en (eg, those <45 years old) or women who are not using hormonal contraception or hormona l 
replacement therapy . However, in the absence of 12 months of amenorrhea, a single FSH 
measurement is insufficient.
** Sterilized men should b e at l east 1 y ear post –bilateral vasectomy and have confirmed that they 
have obtained documentation of the absence of sperm in the ejaculate or have had bilateral 
orchi dectomy .
TAK -831
TAK -831-1005 Page 77of 84
Protocol Incorporating Amendment No. 02 19 March 2018
CONFIDENTIALThe follow ing procedures apply for contraception and pregnancy avoidance.
1.Highly effect ive methods of contraception are defined as “those, alone or in combinat ion, that 
resul t in a l ow failure rate (i e, less than 1% failure rate per y ear when used consistent ly and 
correctly ). In this study, where medications and devices containing ho rmones are excluded, the 
only acceptable methods of contraception are: 
Non-horm onal methods: 
–Intrauterine device.
–Bilateral tubal occlusio n.
–Vasectomized partner (provided that partner is the sole sexual partner of the trial 
participant and that the vase ctomized partner has received medical assessment of the 
surgi cal success.
–True sexual abst inence, only if this is in line wit h the preferred and usual lifestyle o f the 
subject. True abst inence is defined as refraining from heterosexual intercourse during 
the entire period of the study, fro m 1 mo nth before the first dose until 5 half lives PLUS 
30 day s after l ast dose.
Horm onal methods: horm onal contracepti on may  be suscept ible to interaction with the 
investigat ive co mpound, comparator, concomitant medicat ions, which may reduce the 
efficacy  of the contraception method (evaluate on compound-by- compound and protocol –
by-protocol  basis and obtain clinical pharmaco logy justification).
–Combined (estrogen and progestogen) hormonal contraception associated with 
inhibition of  ovul ation initiated at least 3 months before the first dose of study  drug 
OR combined with a barrier method (male condom, female condo m or diaphragm) if 
for shorter durati on unt il she has been on contraceptive for 3 months;
Oral †.
Intravaginal † (eg, ring).
Transdermal †.
–Progestogen -only hormonal contracepti on associ ated wi th inhibit ion of ovulation1 
initiated at least 3 months before the first dose of study  drug OR combined with a 
barrier method (male condo m, female condo m or diaphragm) if shor ter till she has bee n 
on contraceptive for 3 months;
Oral †.
Injectable.
Implantable.
TAK -831
TAK -831-1005 Page 78of 84
Protocol Incorporating Amendment No. 02 19 March 2018
CONFIDENTIAL5.If genotoxicit y/teratogenicit y/embry otoxi city is unlikely  to be caused by  the investi gational 
drug, com parator, background therapy  or standard of care medicationseffect ive methods of 
contraception (there may  be a hi gher than 1% failure rate) are: 
Doubl e-barrier method (contraceptive sponge, diaphragm or cervical cap wit h spermicidal 
jellies or creams PLUS male condo m).
Progestogen only hormonal contraception, where inhib ition of ovulat ion is not the primary 
mode of act ion PLUS condom wit h or without spermicide.
6.Unacceptable methods of contraception are:
Periodic abst inence (eg, calendar, ovulat ion, symptothermal, postovulat ion methods).
Spermicides only .
Withdrawal.
No m ethod at all.
Use of female and male condoms together.
Cap/di aphragm/sponge wi thout spermicide and wit hout condom .
Sexual abst inence is NOT an acceptable method of contraception.
7.Subjects will be provided with information on highly effect ive/effect ive methods of 
contraception as part of the subject informed consent process and will be asked to sign a 
consent form stating that they  understand the requirements for avoidance of pregnancy, 
donati on of  ova, and sperm donat ion during the course of the study .
8.Durin g the course of the study, regular serum hCG pregnancy tests will be performed only for 
wom en of childbearing potential and all subjects (male and female) will receive continued 
guidance wi th respect to the avoidance of pregnancy  and sperm  donat ion as part of the study  
procedures. Such guidance should include a reminder of the fo llowing:
a)Contraceptive requirements of the study .
b)Reasons for use of barrier methods (ie, condom) in male subjects with pregnant partners.
c)Assessment of subject compliance through q uestions such as
i.Have you used the contraception consistent ly and correctly since the last visit ?
ii.Have y ou forgotten to use contraception since the last visit ?
iii.Are y our menses l ate (even in wom en wi th irregular or infrequent menstrual cy cles a 
pregnancy test m ust be performed if the answer is “yes”)
iv.Is there a chance you could be pregnant ?
9.In addit ion to a negative serum hCG pregnancy test at Screening, female subjects of 
childbearing potential must also have confirmed menses in the mo nth before first dosing (no 
delayed menses), a negative serum hCG pregnancy test specify time before receivi ng any dose 
TAK -831
TAK -831-1005 Page 79of 84
Protocol Incorporating Amendment No. 02 19 March 2018
CONFIDENTIALof study medicat ion. In addit ion, subjects must also have a negat ive serum hCG pregnancy test 
specify t ime before receiving first dose of investigational drug as close as possible and before 
first dose of invest igational drug, preferably on the same day .
General Guidance With Respect to the Avoidance of Pregnancy
Such guidance should include a reminder of the fo llowing:
contraceptive requirements of the study .
reasons for use of barrier methods (ie, condom) in males with pregnant partners.
asses sment of subject compliance through questions such as:
–Have you used the contraception consistent ly and correctly since the last visit ?
– H ave y ou forgotten to use contraception since the last visit ? 
–Are y our menses l ate (even in wom en wi th irregular or inf requent m enstrual  cycles a 
pregnancy test must be performed if the answer is “yes”)
–Is there a chance you could be pregnant ?
Pregnancy
Women of childbearing potential will not be included in this study .
If any subject is found to be pregnant during the stu dy she shoul d be wi thdrawn and any 
sponsor -supplied drug should be immediately discontinued. In addit ion, any pregnancies in the 
partner of a male subject during the study  or for (5 half -lives PLUS 90 day s)after the l ast dose, 
shoul d also be recorded foll owing authorizat ion from the subject’s partner. 
Shoul d the pregnancy  occur during or after administration of blinded drug, the invest igator must 
inform  the subject of their right to receive treatment information. If the subject chooses to receive 
unblinde d treatm ent inform ation, the individual blind should be broken by the invest igator. 
Subjects rando mized to placebo need not be fo llowed.
If the female partner of a male subject agrees to the primary care physician being informed, the 
investigator should no tify the primary care physician that the female partner of the subject was 
participat ing in a clinical study at the time she became pregnant and provide details o f the study  
drug the subject received (blinded or unblinded, as applicable).
All pregnancies, including female partners of male subjects, in subjects on active study drug 
(including co mparator, if applicable) will be fo llowed up to final outcome, using the pregnancy  
form. Pregnancies will remain blinded to the study team. The outcome, including any premature 
termination, must be reported to the sponsor. An evaluat ion after the birth o f the child will also be 
conducted. 
TAK-831
TAK-831-1005 Page 80 of 84
Protocol Incorporating Amendment No. 02 19 March 2018
CONFIDENTIALAppendix E Detailed Description of Amendments to Text
The primary sections of the protocol affected by the changes in Amendment No. 02 are indicated. 
The corresponding text has been revised throughout the protocol. 
Change  1: Updated study design and procedures.
The primary change occurs in Section  6.1 Trial Design
Initial 
wording:The study is a double-blind, placeb o-controlled clinical study progressively 
assessing independent cohorts of healthy subjects to continue evaluation of the 
safety, tolerability, PK, and PD of escalati ng single doses (SD) and multiple doses 
(MD) of TAK-831, as either a suspension or T2 tablet formulation, at levels higher 
than those achieved in the initial sing le and multiple rising dose (SRD/MRD) Study 
TAK-831-1001. 
….
In all CSF cohorts, serial lumbar CSF samples will be collected through an 
indwelling temporary catheter on 2 separ ate occasions: the first from Day 1 through 
Day 2, and the second from Day 16 through Day 17, for 24 hours each.
….
Subjects in each cohort will be confined during dosing and be kept in the study unit 
for 24 hours after the last dose for non-CSF cohorts and 48 hours after catheter 
removal in CSF cohorts. The total confinement period in non-CSF cohorts will be 
19 days (Day -2 to Day 17) and 20 days  in CSF cohorts (Day -1 to Day 19). 
Follow-up assessments will occur on Day 30 (±2) for all cohorts.  An exception to 
these minimum confinement periods will be made if a determination is made to 
evaluate QT/QTc intervals for additional single doses of TAK-831 in non-CSF 
cohorts based on the established tolerated dose range.
Amended or 
new wording:The study is a double-blind an investigator and subject blinded, sponsor 
unblinded , placebo-controlled clinical study progressively assessing independent 
cohorts of healthy subjects to continue evaluation of the safety, tolerability, and 
PK, and PD of escalating single doses (SD)  and multiple doses (MD) of TAK-831, 
as either a suspension or T2 tablet formulation, at levels higher than those achieved 
in the initial single and multiple rising dose (SRD/MRD) Study TAK- 831-1001. 
….
In all CSF c ohorts, serial lumbar CSF samples will be collected through either a 
single lumbar puncture or an indwelling temporary catheter on 2 separate 
occasions. In CSF cohorts that use an indwelling temporary catheter on both 
occasions, the first from collection will occur on Day 1 through Day 2, and the 
second from on Day 16 . In CSF cohorts where the predose CSF sample is 
collected through a single lumbar puncture, the first CSF sample will be 
collected on Day -1 prior to the start of  monitoring and the CCI
TAK-831
TAK-831-1005 Page 81 of 84
Protocol Incorporating Amendment No. 02 19 March 2018
CONFIDENTIALsecond collection will be obtained through use of an indwelling temporary 
catheter on Day 17, 16. If an indwelling temporary catheter is being used, it 
will collect serial CSF samples for 24 hours each.
….
Subjects in each cohort will be confined during dosing and be kept in the study unit 
for 24 hours after the last dose for non-CSF cohorts and 48 hours after catheter 
removal in CSF cohorts. The total confinement period in non-CSF cohorts will be 
19 days (Day -2 to Day 17) and 20 da ys in CSF cohorts (Day -1 to Day 19). , 20 
days in CSF cohorts where an indwelling temporary catheter is being used on 
Day 1 and Day 16 (confinement from Day -1 to Day 19); and 21 days in CSF 
cohorts where CSF is collected through a single predose lumbar puncture on 
Day -1 prior to the start of  measurements and through an indwelling catheter on Day 16 (confinement from Day -2 to Day 19). Follow-up 
assessments will occur on Day 30 (±2) for all cohorts. An exception to these minimum confinement periods will be made if  a determination is made to evaluate 
QT/QTc intervals for additional single doses of TAK-831 in non-CSF cohorts 
based on the established tolerated dose range.
The following sections also contain this change:
Title Page
1.0 STUDY SUMMARY
2.0 STUDY SCHEMATIC
3.0 SCHEDULE OF STUDY PROCEDURES
5.1.3 Trial Exploratory Objectives #4
5.2.3 Exploratory Endpoints #3, 4, 5, and 6
6.2 Dose Escalation
Table 6.a Proposed Doses and Cohort Dose Escalation
6.3.1 Rationale of Trial Design
6.3.3.3 Exploratory Endpoints
7.1 Inclusion Criteria
7.2 Exclusion Criteria
7.2.1 Additional Ex clusion Criteria for Cohort(s) With CSF Co llection
7.4.1 Diet and Fluid
9.2.1 Full P hysical Examination
9.2.5.2CCI
CCI
TAK-831
TAK-831-1005 Page 82 of 84
Protocol Incorporating Amendment No. 02 19 March 2018
CONFIDENTIAL9.2.7 Study Drug Administration
9.3.2.1 PD Sample Co llection
9.3.2 PD Meas urements
9.3.5 Confinement
11.1 S tatistical and Analyt ical Plans
11.2 Interim Analysis and Criteria for Early Termination
Rationale for Change : Allow combination of CSF measurements at baseline and  
monitoring, clarifications, and c orrections/editorial changes.
Change  2: Updated clinical study material management.
The primary change occurs in Section  8.0 CLINICAL STUDY MATERIAL MANAGEMENT.
Initial 
wording:8.1 Clinical Study Drug
Clinical study drug will be packaged to support enrollment.
8.1.1 Clinical Study Drug Labeling
Clinical study drug will be affixed wi th a clinical label in accordance with 
regulatory requirements.
8.1.2 Clinical Study Drug Inventory and Storage
Clinical study drug must be stored in a secure, limited-access location under the 
storage conditions specified on the label. Inventory (receipt and dispensing) of 
study drug must be recorded by an authorized person at the study site.
8.1.3 Clinical Study Drug Blinding
This is an investigator and subject blinded, sponsor unblinded study. The study
drug blind is maintained through a randomization schedule held by the 
randomizatio n personnel. Investigational drug w ill be dispensed in a manner so as 
to minimize the possibility of identif ication of different doses and p lacebo through 
appearance. Further details will be provided in the Pharmacy Manual.
8.1.4 Randomization Code Creation and Storage
Takeda Analytical Sciences Department or designee will generate the 
randomization schedule. All ra ndomization information will be stored in a secured 
area, accessible only by authorized personnel. 
8.1.5 Clinical Trial Blind Maintenance/Unblinding Procedure
….The investigational drug blind shall not be broken by the investigator unless 
information concerning the investigatio nal drug is necessary for the medical CCI
TAK -831
TAK -831-1005 Page 83of 84
Protocol Incorporating Amendment No. 02 19 March 2018
CONFIDENTIALtreatm ent of the subject. All study  assessments and causalit y shoul d be perform ed, 
if possible, before unblinding. In the event of a medical emergency, if possible, the 
medical mo nitor or designee should be contacted before the invest igational drug 
blind is broken to discuss the need for unblinding. The sponsor must be notified as 
soon as possible if the investigational drug blind is broken .
Individual code break envelopes will be prov ided for all subjects by the sponsor or 
designee. Each sealed envelope containing the randomizat ion code and treatment 
will be kept in a medicat ion storage room, which is locked with restricted access. If 
opened, the name o f the person who opened it, the date and time o f opening and the 
reason for opening must be written on the envelope. A similar mechanism may be 
subst ituted for envelopes (eg, scratch -off cards).
Amended or 
new wording:….
8.1 Clinical Study Drug
Details regarding the active drug and placebo in tablet dosage form and the 
extemporaneous preparation can be found in the IB and compounding 
manual respectively. Clinical study  drug will  be packaged to support enrollment 
and replacement subjects as required. When a replacement subject is 
required, the sponsor needs to be contacted prior to dosing.
8.1.1 Clinical Study Drug Labeling
Clinical study  drug will  be affixed wit h a clinical label in accordance with 
regul atory  requi rements.
8.1.2 Clinical Study Drug Inventory and Storage
Clinical s tudy drug m ust be stored in a secure, limited -access location under and 
remained in the original container until dispensed. The storage conditions 
specified on condition and temperature excursion information can be found in 
the label. Inventory  (recei ptcompo unding manual. Receipt and dispensing of 
study  drug m ust be recorded by  anauthori zed person personnel at the study trial 
site.
8.1.3 Clinical Study Drug Blinding
This is an invest igator and subject blinded, sponsor -open study. The investigator 
and subjects a re blinded to treatment assignment. The unblinded study . The 
study drug supply will be provided to an unblinded pharmacist or other 
qualified trial site personnel who will blind is maintained through athe trial 
supplies. Treatment identity (name and strength or potency) will be included 
on the study drug container label; rando mizat ion schedule held by the 
rando mizat ion personnel. Invest igational drug will be dispensed in a manner 
socode/disclosure envelopes or lists will be provided as to minimize the
possibilit y of ident ificat ion of different doses and placebo through appearance. 
TAK -831
TAK -831-1005 Page 84of 84
Protocol Incorporating Amendment No. 02 19 March 2018
CONFIDENTIALFurther details will be provided in the Pharmacy  Manual per site procedure .
8.1.4 Randomization Code Creation and Storage
Takeda Analy tical Sciences Depart mentRandomization personnel of the 
sponsor or desi gnee will  generate the randomizat ion schedule. All randomizat ion 
inform ation will be stored in a secured area, accessible only by authorized 
personnel. 
8.1.5 Clinical Trial Blind Maintenance/Unblinding Procedure
….
The inv estigational drug blind shall not be broken by  the investi gator unless 
inform ation concerning the invest igational drug i s necessary  for the m edical  
treatm ent of the subject. AllThe investigator should perform all study  
assessments and causalit y shoul d be p erformed evaluation , if possible, before 
unblinding. In the event of a medical emergency, if possible, the medical mo nitor 
or desi gnee shoul d be contacted before the invest igational drug blind is broken to 
discuss the need for unblinding. The sponsor must b e notified as soon as possible if 
the invest igational drug blind is broken .
Individual code break envelopes will be provided for all subjects to the 
investigator or designee by the sponsor or designee. Each sealed envelope 
containing the rando mizat ion code and treatment will be kept in a medicat ion 
storage room , which i s locked wi th restri cted access. If opened, the name of the 
person who opened it, the date and time of openi ng and the reason for opening must 
be written on the envelope. A similar mechanism may be subst ituted for envelopes 
(eg, scratch -off cards).
….
Rationale for Change: Clarificat ion of procedure.
 䢢
䢢䢢䢢
䢢
䢢䢢
䢢
(/(&7521,& 6,*1$785(6 
Signed by Meaning of Signature Server Date 
(dd-MMM-yyyy HH:mm ‘UTC’) 

  

  

  

  

   


   


   


   


   


   


   


   


   


   


   


   


   


   


   



GGF䣃䢢䣔䣣䣰䣦䣱䣯䣫䣼䣧䣦䢮䢢䣋䣰䣸䣧䣵䣶䣫䣩䣣䣶䣱䣴䢢䣣䣰䣦䢢䣕䣷䣤䣬䣧䣥䣶䢢䣄䣮䣫䣰䣦䣧䣦䢮䢢䣕䣲䣱䣰䣵䣱䣴䢢䣗䣰䣤䣮䣫䣰䣦 䣧䣦䢮䢢䣒䣮䣣䣥䣧䣤䣱䢯䣅䣱䣰䣶䣴䣱䣮䣮䣧䣦䢮䢢䣒䣪䣣䣵䣧䢢䢳䢢䣕䣶䣷䣦䣻䢢䣶䣱
䣇䣸䣣䣮䣷䣣䣶䣧䢢䣕䣣䣨䣧䣶䣻䢮䢢䣖䣱䣮䣧䣴䣣䣤䣫䣮䣫䣶䣻䢮䢢䣣䣰䣦䢢䣒䣪䣣䣴䣯䣣䣥䣱䣭䣫䣰䣧䣶䣫䣥䣵䢢䣱䣨䢢䣇䣵䣥䣣䣮䣣䣶䣫 䣰䣩䢢䣏䣷䣮䣶䣫䣲䣮䣧䢢䣆䣱䣵䣧䣵䢢䣱䣨䢢䣖䣃䣍䢯䢺䢵䢳䢢䣫䣰䢢䣊䣧䣣䣮䣶䣪䣻䢢䣕䣷䣤䣬䣧䣥䣶䣵
&OLQLFDO6FLHQFH$SSURYDO 0DU87&
%LRVWDWLVWLFV$SSURYDO 0DU87&
&OLQLFDO93$SSURYDO 0DU87&
&OLQLFDO3KDUPDFRORJ\$SSURYDO 0DU87&PPD